WO2022095960A1 - 用于癌症治疗的KRas抑制剂 - Google Patents
用于癌症治疗的KRas抑制剂 Download PDFInfo
- Publication number
- WO2022095960A1 WO2022095960A1 PCT/CN2021/128977 CN2021128977W WO2022095960A1 WO 2022095960 A1 WO2022095960 A1 WO 2022095960A1 CN 2021128977 W CN2021128977 W CN 2021128977W WO 2022095960 A1 WO2022095960 A1 WO 2022095960A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- alkyl
- halogen
- compound
- formula
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 81
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 229940124785 KRAS inhibitor Drugs 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 337
- 238000000034 method Methods 0.000 claims abstract description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 122
- 125000000217 alkyl group Chemical group 0.000 claims description 116
- 101150105104 Kras gene Proteins 0.000 claims description 101
- 150000002367 halogens Chemical class 0.000 claims description 101
- 230000035772 mutation Effects 0.000 claims description 100
- 102000016914 ras Proteins Human genes 0.000 claims description 78
- 108010014186 ras Proteins Proteins 0.000 claims description 78
- 150000003839 salts Chemical class 0.000 claims description 78
- 125000005842 heteroatom Chemical group 0.000 claims description 66
- 239000012453 solvate Substances 0.000 claims description 66
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 55
- 229910052760 oxygen Inorganic materials 0.000 claims description 54
- 229910052717 sulfur Inorganic materials 0.000 claims description 53
- 102200006538 rs121913530 Human genes 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 33
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 32
- 229910052799 carbon Inorganic materials 0.000 claims description 31
- 125000004429 atom Chemical group 0.000 claims description 30
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 27
- 230000001404 mediated effect Effects 0.000 claims description 27
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 19
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 14
- 201000002528 pancreatic cancer Diseases 0.000 claims description 14
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 10
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 206010038038 rectal cancer Diseases 0.000 claims description 9
- 201000001275 rectum cancer Diseases 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 7
- 206010004593 Bile duct cancer Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 201000007455 central nervous system cancer Diseases 0.000 claims description 6
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010006143 Brain stem glioma Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 3
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 3
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 3
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims description 3
- 206010046392 Ureteric cancer Diseases 0.000 claims description 3
- 206010046431 Urethral cancer Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000005969 Uveal melanoma Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 3
- 210000000750 endocrine system Anatomy 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims description 3
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000002575 ocular melanoma Diseases 0.000 claims description 3
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000003708 skin melanoma Diseases 0.000 claims description 3
- 208000037959 spinal tumor Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000011294 ureter cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 133
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 133
- 238000006243 chemical reaction Methods 0.000 description 107
- -1 cycloaliphatic Chemical group 0.000 description 104
- 239000000243 solution Substances 0.000 description 69
- 210000004027 cell Anatomy 0.000 description 61
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- 239000000543 intermediate Substances 0.000 description 53
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 51
- 230000015572 biosynthetic process Effects 0.000 description 47
- 238000003786 synthesis reaction Methods 0.000 description 47
- 238000005481 NMR spectroscopy Methods 0.000 description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 35
- 239000007787 solid Substances 0.000 description 34
- 230000002401 inhibitory effect Effects 0.000 description 31
- 239000000203 mixture Substances 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 239000000651 prodrug Substances 0.000 description 26
- 229940002612 prodrug Drugs 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 125000001424 substituent group Chemical group 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 102200006532 rs112445441 Human genes 0.000 description 19
- 102200006539 rs121913529 Human genes 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- 239000013543 active substance Substances 0.000 description 18
- 239000012043 crude product Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 239000012091 fetal bovine serum Substances 0.000 description 18
- 239000011734 sodium Substances 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 238000003818 flash chromatography Methods 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 16
- 239000012980 RPMI-1640 medium Substances 0.000 description 15
- 229910004298 SiO 2 Inorganic materials 0.000 description 15
- 230000037396 body weight Effects 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 11
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 11
- 125000002950 monocyclic group Chemical group 0.000 description 11
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 11
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 125000005037 alkyl phenyl group Chemical group 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 229910052801 chlorine Inorganic materials 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZQDPDWALEXQWLI-UHFFFAOYSA-N [7-fluoro-2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-benzothiazol-4-yl]boronic acid Chemical compound C(C)(C)(C)OC(=O)NC=1SC2=C(N=1)C(=CC=C2F)B(O)O ZQDPDWALEXQWLI-UHFFFAOYSA-N 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 9
- 238000012054 celltiter-glo Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 125000003367 polycyclic group Chemical group 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- PZVTZURWPMLUHB-UHFFFAOYSA-N tert-butyl 4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinolin-4-yl)piperazine-1-carboxylate Chemical compound BrC1=C(C=C2C(=C(C(=NC2=C1F)Cl)C#N)N1CCN(CC1)C(=O)OC(C)(C)C)Cl PZVTZURWPMLUHB-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000008300 Mutant Proteins Human genes 0.000 description 7
- 108010021466 Mutant Proteins Proteins 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 230000006806 disease prevention Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- 125000004193 piperazinyl group Chemical group 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 230000000155 isotopic effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 6
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 5
- SIXMIICHKQBUTQ-SNVBAGLBSA-N C[C@H](CN(CC1)C(C(C(N=C2Cl)=C3F)=CC(Cl)=C3Br)=C2C#N)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(CC1)C(C(C(N=C2Cl)=C3F)=CC(Cl)=C3Br)=C2C#N)N1C(OC(C)(C)C)=O SIXMIICHKQBUTQ-SNVBAGLBSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- ZQXJZRTVKRNHKP-KRWDZBQOSA-N N#CC[C@@H](CN(CC1)C(C(C(N=C2)=C3F)=CC(Cl)=C3Br)=C2C#N)N1C(OCC1=CC=CC=C1)=O Chemical compound N#CC[C@@H](CN(CC1)C(C(C(N=C2)=C3F)=CC(Cl)=C3Br)=C2C#N)N1C(OCC1=CC=CC=C1)=O ZQXJZRTVKRNHKP-KRWDZBQOSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- OFYQEYPITRRCBP-UHFFFAOYSA-N [3-[(dimethylamino)methyl]phenyl]boronic acid Chemical compound CN(C)CC1=CC=CC(B(O)O)=C1 OFYQEYPITRRCBP-UHFFFAOYSA-N 0.000 description 5
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 210000001853 liver microsome Anatomy 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- VFMMPHCGEFXGIP-UHFFFAOYSA-N 7,8-Benzoflavone Chemical compound O1C2=C3C=CC=CC3=CC=C2C(=O)C=C1C1=CC=CC=C1 VFMMPHCGEFXGIP-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- ZZKIKDSDTFTOQX-NIKGAXFTSA-N C[C@H](CN(CC1)C(C(C(N=C2O[C@H](CN(C)C3)[C@@H]3OC)=C3F)=CC(Cl)=C3Br)=C2C#N)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(CC1)C(C(C(N=C2O[C@H](CN(C)C3)[C@@H]3OC)=C3F)=CC(Cl)=C3Br)=C2C#N)N1C(OC(C)(C)C)=O ZZKIKDSDTFTOQX-NIKGAXFTSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 4
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 4
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 4
- 108091006109 GTPases Proteins 0.000 description 4
- 101150117869 Hras gene Proteins 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- FLXNUPRSIJJXBZ-LBPRGKRZSA-N NC1=NC(C(C(C(F)=C(C2=C3)N=CC(C#N)=C2N2C[C@H](CC#N)NCC2)=C3Cl)=CC=C2F)=C2S1 Chemical compound NC1=NC(C(C(C(F)=C(C2=C3)N=CC(C#N)=C2N2C[C@H](CC#N)NCC2)=C3Cl)=CC=C2F)=C2S1 FLXNUPRSIJJXBZ-LBPRGKRZSA-N 0.000 description 4
- 101150073096 NRAS gene Proteins 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
- 108700042226 ras Genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- HPEWUKWQCONIRH-UHFFFAOYSA-N (2-bromo-5-fluorophenyl)thiourea Chemical compound NC(=S)Nc1cc(F)ccc1Br HPEWUKWQCONIRH-UHFFFAOYSA-N 0.000 description 3
- WVGMGFKCXPENCY-PHDIDXHHSA-N (3R,4R)-4-methoxy-1-methylpyrrolidin-3-ol Chemical compound CO[C@@H]1CN(C)C[C@H]1O WVGMGFKCXPENCY-PHDIDXHHSA-N 0.000 description 3
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- HDKYIPMDJJVHHA-UHFFFAOYSA-N 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid Chemical compound Nc1c(F)c(Br)c(Cl)cc1C(O)=O HDKYIPMDJJVHHA-UHFFFAOYSA-N 0.000 description 3
- MLXSRTXYRGAHOE-UHFFFAOYSA-N 2-chloro-3-fluoro-5-iodopyridin-4-amine Chemical compound NC1=C(I)C=NC(Cl)=C1F MLXSRTXYRGAHOE-UHFFFAOYSA-N 0.000 description 3
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 3
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- CSKDUEJNNJZLBL-UHFFFAOYSA-N 7-bromo-2,4,6-trichloro-8-fluoroquinoline-3-carbonitrile Chemical compound BrC1=C(C=C2C(=C(C(=NC2=C1F)Cl)C#N)Cl)Cl CSKDUEJNNJZLBL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- ZCJMDPBGPULLKH-AWEZNQCLSA-N C=CC(N(CC1)[C@@H](CC#N)CN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1)=C1C#N)=O Chemical compound C=CC(N(CC1)[C@@H](CC#N)CN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1)=C1C#N)=O ZCJMDPBGPULLKH-AWEZNQCLSA-N 0.000 description 3
- KYIUCLGVFHUJQQ-LBPRGKRZSA-N C=CC(N(CC1)[C@@H](CC#N)CN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1O)=C1C#N)=O Chemical compound C=CC(N(CC1)[C@@H](CC#N)CN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1O)=C1C#N)=O KYIUCLGVFHUJQQ-LBPRGKRZSA-N 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- DFBRFVNVUBHMTF-UHFFFAOYSA-N N#CC(C(Cl)=NC(C1=CN=C2Cl)=C2F)=C1Cl Chemical compound N#CC(C(Cl)=NC(C1=CN=C2Cl)=C2F)=C1Cl DFBRFVNVUBHMTF-UHFFFAOYSA-N 0.000 description 3
- VPPJELHWVGWKTL-HNNXBMFYSA-N N#CC[C@@H](CN(CC1)C(C(C(N=C2O)=C3F)=CC(Cl)=C3Br)=C2C#N)N1C(OCC1=CC=CC=C1)=O Chemical compound N#CC[C@@H](CN(CC1)C(C(C(N=C2O)=C3F)=CC(Cl)=C3Br)=C2C#N)N1C(OCC1=CC=CC=C1)=O VPPJELHWVGWKTL-HNNXBMFYSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005660 chlorination reaction Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229940125399 kras g12c inhibitor Drugs 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- KXCLZRJHAIASTC-UHFFFAOYSA-N methyl 2-amino-4-bromo-5-chloro-3-fluorobenzoate Chemical compound COC(=O)c1cc(Cl)c(Br)c(F)c1N KXCLZRJHAIASTC-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000007781 signaling event Effects 0.000 description 3
- DATRVIMZZZVHMP-MRVPVSSYSA-N tert-butyl (2r)-2-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-MRVPVSSYSA-N 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001875 tumorinhibitory effect Effects 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 238000012447 xenograft mouse model Methods 0.000 description 3
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- KNYHISBJRQVMAZ-UHFFFAOYSA-N 1h-pyrazolo[3,4-c]pyridine Chemical compound N1=CC=C2C=NNC2=C1 KNYHISBJRQVMAZ-UHFFFAOYSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 description 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- VGBNFHCMMDOOFO-GFCCVEGCSA-N 7-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-6-chloro-8-fluoro-4-[(3R)-3-methyl-4-prop-2-enoylpiperazin-1-yl]quinoline-3-carbonitrile Chemical compound C[C@H](CN(CC1)C(C(C=C(C(C(C2=C3SC(N)=N2)=CC=C3F)=C2F)Cl)=C2N=C2)=C2C#N)N1C(C=C)=O VGBNFHCMMDOOFO-GFCCVEGCSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NLZXRRHJMFSSTR-UHFFFAOYSA-N C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1N)=C1C#N)=O Chemical compound C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1N)=C1C#N)=O NLZXRRHJMFSSTR-UHFFFAOYSA-N 0.000 description 2
- RLTOEEWONICAEU-UHFFFAOYSA-N C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1O)=C1C#N)=O Chemical compound C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1O)=C1C#N)=O RLTOEEWONICAEU-UHFFFAOYSA-N 0.000 description 2
- YIVZLGOZPWOHOB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1C#C[Si](C)(C)C)=C2F)=CC(Cl)=C2Br)=C1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1C#C[Si](C)(C)C)=C2F)=CC(Cl)=C2Br)=C1C#N)=O YIVZLGOZPWOHOB-UHFFFAOYSA-N 0.000 description 2
- KQFPLDIGOJWYEC-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1C)=C2F)=CC(Cl)=C2Br)=C1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1C)=C2F)=CC(Cl)=C2Br)=C1C#N)=O KQFPLDIGOJWYEC-UHFFFAOYSA-N 0.000 description 2
- NGHKZQGTBWVKDQ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1NC(C)=O)=C2F)=CC(Cl)=C2Br)=C1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1NC(C)=O)=C2F)=CC(Cl)=C2Br)=C1C#N)=O NGHKZQGTBWVKDQ-UHFFFAOYSA-N 0.000 description 2
- XZWPMDKAFDEXQT-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C(C(NC1(O)Cl)=C2F)=CC(Cl)=C2Br)=C1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C(C(NC1(O)Cl)=C2F)=CC(Cl)=C2Br)=C1C#N)=O XZWPMDKAFDEXQT-UHFFFAOYSA-N 0.000 description 2
- FIGSYPJGFXEOIN-UHFFFAOYSA-N CC(C)(C)OC(NC1=NC(C(C(C(F)=C(C(C(N(CC2)CCN2C(OC(C)(C)C)=O)=C2C#N)=C3)N=C2C#C)=C3Cl)=CC=C2F)=C2S1)=O Chemical compound CC(C)(C)OC(NC1=NC(C(C(C(F)=C(C(C(N(CC2)CCN2C(OC(C)(C)C)=O)=C2C#N)=C3)N=C2C#C)=C3Cl)=CC=C2F)=C2S1)=O FIGSYPJGFXEOIN-UHFFFAOYSA-N 0.000 description 2
- ZEDFFHXLLDGAGL-UHFFFAOYSA-N CC(NC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F)=O Chemical compound CC(NC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F)=O ZEDFFHXLLDGAGL-UHFFFAOYSA-N 0.000 description 2
- VCKZQFAZKDTPHF-UHFFFAOYSA-N CCOC(C(C(NC(CC#N)=O)=C1F)=CN=C1Cl)=O Chemical compound CCOC(C(C(NC(CC#N)=O)=C1F)=CN=C1Cl)=O VCKZQFAZKDTPHF-UHFFFAOYSA-N 0.000 description 2
- HIYUQAGDTJZLQD-UHFFFAOYSA-N CN(C)CC1=CC=CC(C(C(C#N)=C(C2=CC(Cl)=C3C(C4=C5SC(N)=N4)=CC=C5F)N(CC4)CCN4C(C=C)=O)=NC2=C3F)=C1 Chemical compound CN(C)CC1=CC=CC(C(C(C#N)=C(C2=CC(Cl)=C3C(C4=C5SC(N)=N4)=CC=C5F)N(CC4)CCN4C(C=C)=O)=NC2=C3F)=C1 HIYUQAGDTJZLQD-UHFFFAOYSA-N 0.000 description 2
- SHGKJRNUGOKMGE-UHFFFAOYSA-N CN(C)CCN1N=CC=C1B(O)O Chemical compound CN(C)CCN1N=CC=C1B(O)O SHGKJRNUGOKMGE-UHFFFAOYSA-N 0.000 description 2
- XLUMKOVUAXAWHB-UHFFFAOYSA-N CN1CC2=CC=CC(C(C(C#N)=C(C3=CC(Cl)=C4C(C5=C6SC(N)=N5)=CC=C6F)N(CC5)CCN5C(C=C)=O)=NC3=C4F)=C2CC1 Chemical compound CN1CC2=CC=CC(C(C(C#N)=C(C3=CC(Cl)=C4C(C5=C6SC(N)=N5)=CC=C6F)N(CC5)CCN5C(C=C)=O)=NC3=C4F)=C2CC1 XLUMKOVUAXAWHB-UHFFFAOYSA-N 0.000 description 2
- SPSUGNAROIDQBZ-UHFFFAOYSA-N CNC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F Chemical compound CNC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F SPSUGNAROIDQBZ-UHFFFAOYSA-N 0.000 description 2
- NKFTXLJESCHKRF-UHFFFAOYSA-N COC(C(C(C1=C2SC(N)=N1)=CC=C2F)=C(C=C12)Cl)=C1N=CC(C#N)=C2N(CC1)CCN1C(C=C)=O Chemical compound COC(C(C(C1=C2SC(N)=N1)=CC=C2F)=C(C=C12)Cl)=C1N=CC(C#N)=C2N(CC1)CCN1C(C=C)=O NKFTXLJESCHKRF-UHFFFAOYSA-N 0.000 description 2
- RZTFCHIAKFWLPM-UJUVCNOISA-N C[C@H](CN(CC1)C(C2=CC(Cl)=C(C(C3=C4SC(N)=N3)=CC=C4F)C(F)=C2N=C2O[C@H](CN(C)C3)[C@@H]3OC)=C2C#N)N1C(C=C)=O Chemical compound C[C@H](CN(CC1)C(C2=CC(Cl)=C(C(C3=C4SC(N)=N3)=CC=C4F)C(F)=C2N=C2O[C@H](CN(C)C3)[C@@H]3OC)=C2C#N)N1C(C=C)=O RZTFCHIAKFWLPM-UJUVCNOISA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NHXBEAGRPVOUPD-UHFFFAOYSA-N N#CC(C(Cl)=NC(C1=CC(Cl)=C2Br)=C2F)=C1N1CCNCC1 Chemical compound N#CC(C(Cl)=NC(C1=CC(Cl)=C2Br)=C2F)=C1N1CCNCC1 NHXBEAGRPVOUPD-UHFFFAOYSA-N 0.000 description 2
- KZBUSLLMGMXYBJ-UHFFFAOYSA-N N#CC(C(N=C(C1=CC=CC=C1)C1=CC=CC=C1)=NC(C1=CC(Cl)=C2Br)=C2F)=C1N(CC1)CCN1C(O)=O Chemical compound N#CC(C(N=C(C1=CC=CC=C1)C1=CC=CC=C1)=NC(C1=CC(Cl)=C2Br)=C2F)=C1N(CC1)CCN1C(O)=O KZBUSLLMGMXYBJ-UHFFFAOYSA-N 0.000 description 2
- GHCQRZNOUYKOMA-HNNXBMFYSA-N N#CC[C@@H](CN(CC1)C(C(C(N=C2Cl)=C3F)=CC(Cl)=C3Br)=C2C#N)N1C(OCC1=CC=CC=C1)=O Chemical compound N#CC[C@@H](CN(CC1)C(C(C(N=C2Cl)=C3F)=CC(Cl)=C3Br)=C2C#N)N1C(OCC1=CC=CC=C1)=O GHCQRZNOUYKOMA-HNNXBMFYSA-N 0.000 description 2
- UPGYCCQXVFSVFS-UHFFFAOYSA-N NC1=NC(C(C(C(F)=C(C(C(N2CCNCC2)=C2C#N)=C3)N=C2N=C(C2=CC=CC=C2)C2=CC=CC=C2)=C3Cl)=CC=C2F)=C2S1 Chemical compound NC1=NC(C(C(C(F)=C(C(C(N2CCNCC2)=C2C#N)=C3)N=C2N=C(C2=CC=CC=C2)C2=CC=CC=C2)=C3Cl)=CC=C2F)=C2S1 UPGYCCQXVFSVFS-UHFFFAOYSA-N 0.000 description 2
- LYKNTIZYXNWJHC-UHFFFAOYSA-N O=C(C1=CC=CC=C1)NS(CNC(C=C(C=C1)F)=C1Br)(=O)=O Chemical compound O=C(C1=CC=CC=C1)NS(CNC(C=C(C=C1)F)=C1Br)(=O)=O LYKNTIZYXNWJHC-UHFFFAOYSA-N 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 101150040459 RAS gene Proteins 0.000 description 2
- 229940078123 Ras inhibitor Drugs 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940124988 adagrasib Drugs 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000003388 anti-hormonal effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012200 cell viability kit Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000003838 furazanyl group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 229960001404 quinidine Drugs 0.000 description 2
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- PZJCPKURKHCJSQ-LLVKDONJSA-N tert-butyl (2R)-4-(7-bromo-6-chloro-3-cyano-8-fluoroquinolin-4-yl)-2-methylpiperazine-1-carboxylate Chemical compound C[C@H](CN(CC1)C(C(C(N=C2)=C3F)=CC(Cl)=C3Br)=C2C#N)N1C(OC(C)(C)C)=O PZJCPKURKHCJSQ-LLVKDONJSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- WYWWVJHQDVCHKF-ITGWJZMWSA-J tetrasodium;[(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-[[[[(2r,3s,4r,5r)-5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](OP([O-])([O-])=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 WYWWVJHQDVCHKF-ITGWJZMWSA-J 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000002053 thietanyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SWUMSPVHWLBEHP-UHFFFAOYSA-N (1,3-dimethylpyrazol-4-yl)boronic acid Chemical compound CC1=NN(C)C=C1B(O)O SWUMSPVHWLBEHP-UHFFFAOYSA-N 0.000 description 1
- KKVZONPEMODBBG-UHFFFAOYSA-N (1-hydroxydodecane-1,1-diyl)bis(phosphonic acid) Chemical compound CCCCCCCCCCCC(O)(P(O)(O)=O)P(O)(O)=O KKVZONPEMODBBG-UHFFFAOYSA-N 0.000 description 1
- MGNBKNBEZGLHNF-UHFFFAOYSA-N (2-methylpyrazol-3-yl)boronic acid Chemical compound CN1N=CC=C1B(O)O MGNBKNBEZGLHNF-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006707 (C3-C12) heterocycloalkyl group Chemical group 0.000 description 1
- 239000001211 (E)-4-phenylbut-3-en-2-one Substances 0.000 description 1
- GMHKMTDVRCWUDX-LBPRGKRZSA-N (S)-Mephenytoin Chemical compound C=1C=CC=CC=1[C@]1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-LBPRGKRZSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FHLXQXCQSUICIN-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrido[3,2-d]pyrimidine Chemical class C1=CC=C2NCNCC2=N1 FHLXQXCQSUICIN-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 1
- MXBVNILGVJVVMH-UHFFFAOYSA-N 1,7-naphthyridine Chemical compound C1=NC=CC2=CC=CN=C21 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- 229940044613 1-propanol Drugs 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- UVVVFGSFGDHACP-UHFFFAOYSA-N 1h-indole;1h-pyrrole Chemical compound C=1C=CNC=1.C1=CC=C2NC=CC2=C1 UVVVFGSFGDHACP-UHFFFAOYSA-N 0.000 description 1
- DDZGQYREBDXECY-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyrazine Chemical compound C1=CN=C2C=NNC2=N1 DDZGQYREBDXECY-UHFFFAOYSA-N 0.000 description 1
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 description 1
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
- WCXFPLXZZSWROM-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridine Chemical compound C1=NC=C2C=NNC2=C1 WCXFPLXZZSWROM-UHFFFAOYSA-N 0.000 description 1
- XLKDJOPOOHHZAN-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine Chemical compound C1=NC=C2NC=CC2=C1 XLKDJOPOOHHZAN-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- SRSKXJVMVSSSHB-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]pyridine Chemical compound N1=CC=C2NC=CC2=C1 SRSKXJVMVSSSHB-UHFFFAOYSA-N 0.000 description 1
- SSNMISUJOQAFRR-UHFFFAOYSA-N 2,6-naphthyridine Chemical compound N1=CC=C2C=NC=CC2=C1 SSNMISUJOQAFRR-UHFFFAOYSA-N 0.000 description 1
- HCMMECMKVPHMDE-UHFFFAOYSA-N 2,7-naphthyridine Chemical compound C1=NC=C2C=NC=CC2=C1 HCMMECMKVPHMDE-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- MGDKBCNOUDORNI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;potassium Chemical compound [K].[K].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O MGDKBCNOUDORNI-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SFRJQFICUQFDFU-UHFFFAOYSA-N 2-amino-4-bromo-3-fluorobenzoic acid Chemical compound NC1=C(F)C(Br)=CC=C1C(O)=O SFRJQFICUQFDFU-UHFFFAOYSA-N 0.000 description 1
- FWTXFEKVHSFTDQ-UHFFFAOYSA-N 2-bromo-5-fluoroaniline Chemical compound NC1=CC(F)=CC=C1Br FWTXFEKVHSFTDQ-UHFFFAOYSA-N 0.000 description 1
- VUGYOFOYGPXOFL-UHFFFAOYSA-N 2-chloro-3-fluoropyridin-4-amine Chemical compound NC1=CC=NC(Cl)=C1F VUGYOFOYGPXOFL-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- TYCFGHUTYSLISP-UHFFFAOYSA-N 2-fluoroprop-2-enoic acid Chemical compound OC(=O)C(F)=C TYCFGHUTYSLISP-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- AOPRXJXHLWYPQR-UHFFFAOYSA-N 2-phenoxyacetamide Chemical class NC(=O)COC1=CC=CC=C1 AOPRXJXHLWYPQR-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 description 1
- QXESCLUBODNILR-UHFFFAOYSA-N 4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinolin-4-yl)piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCN(CC1)c1c(C#N)c(Cl)nc2c(F)c(Br)c(Cl)cc12 QXESCLUBODNILR-UHFFFAOYSA-N 0.000 description 1
- MTERSQYMYBGZTP-UHFFFAOYSA-N 4-amino-n-(5-methyl-2-phenylpyrazol-3-yl)benzenesulfonamide Chemical compound C=1C=CC=CC=1N1N=C(C)C=C1NS(=O)(=O)C1=CC=C(N)C=C1 MTERSQYMYBGZTP-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- RYKHFTUPXZCSCU-UHFFFAOYSA-N B(O)(O)OC1=CC=CC(=C1)CN(C)C Chemical compound B(O)(O)OC1=CC=CC(=C1)CN(C)C RYKHFTUPXZCSCU-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OIISKEGFGKEKOT-UHFFFAOYSA-N C1(CCC(N1)=O)=O.[I] Chemical compound C1(CCC(N1)=O)=O.[I] OIISKEGFGKEKOT-UHFFFAOYSA-N 0.000 description 1
- ULYWHNCHVKXTOT-UHFFFAOYSA-N C=C(C(N(CC1)CCN1C1=C(C=C(C(C(C2=C3SC(N)=N2)=CC=C3F)=C2F)Cl)C2=NC=C1C#N)=O)F Chemical compound C=C(C(N(CC1)CCN1C1=C(C=C(C(C(C2=C3SC(N)=N2)=CC=C3F)=C2F)Cl)C2=NC=C1C#N)=O)F ULYWHNCHVKXTOT-UHFFFAOYSA-N 0.000 description 1
- QRXCOJPMOCLESS-UHFFFAOYSA-N C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C(C2=C(C=C3)SC(N)=N2)=C3F)C(F)=C1N=C1N)=C1C#N)=O Chemical compound C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C(C2=C(C=C3)SC(N)=N2)=C3F)C(F)=C1N=C1N)=C1C#N)=O QRXCOJPMOCLESS-UHFFFAOYSA-N 0.000 description 1
- GTXWGEJZUAAMKZ-UHFFFAOYSA-N C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1C#C)=C1C#N)=O Chemical compound C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1C#C)=C1C#N)=O GTXWGEJZUAAMKZ-UHFFFAOYSA-N 0.000 description 1
- FZLVJMRRRAZRQY-UHFFFAOYSA-N C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1C2CC2)=C1C#N)=O Chemical compound C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C(C2=C3SC(N)=N2)=CC=C3F)C(F)=C1N=C1C2CC2)=C1C#N)=O FZLVJMRRRAZRQY-UHFFFAOYSA-N 0.000 description 1
- BHNQKJWTFFLOHS-UHFFFAOYSA-N C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C2=CC=CC3=C2N=C(N)S3)C(F)=C1N=C1N)=C1C#N)=O Chemical compound C=CC(N(CC1)CCN1C(C1=CC(Cl)=C(C2=CC=CC3=C2N=C(N)S3)C(F)=C1N=C1N)=C1C#N)=O BHNQKJWTFFLOHS-UHFFFAOYSA-N 0.000 description 1
- XGKYCXJEQJEMIH-UHFFFAOYSA-N CC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F Chemical compound CC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F XGKYCXJEQJEMIH-UHFFFAOYSA-N 0.000 description 1
- LSVMHIQJRQOSRI-AWEZNQCLSA-N CC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)C[C@H](CC#N)N3C(C=C)=O)=NC1=C2F Chemical compound CC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)C[C@H](CC#N)N3C(C=C)=O)=NC1=C2F LSVMHIQJRQOSRI-AWEZNQCLSA-N 0.000 description 1
- VZZDFSRWVGUNAC-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1C2=C(CCN(C)C3)C3=CC=C2)=C2F)=CC(Cl)=C2Br)=C1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1C2=C(CCN(C)C3)C3=CC=C2)=C2F)=CC(Cl)=C2Br)=C1C#N)=O VZZDFSRWVGUNAC-UHFFFAOYSA-N 0.000 description 1
- GYRRLBQGXFSMHP-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1C2=CC(CN(C)C)=CC=C2)=C2F)=CC(Cl)=C2Br)=C1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1C2=CC(CN(C)C)=CC=C2)=C2F)=CC(Cl)=C2Br)=C1C#N)=O GYRRLBQGXFSMHP-UHFFFAOYSA-N 0.000 description 1
- OMOUJVVCKGCADV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1Cl)=C2F)=CN=C2Cl)=C1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1Cl)=C2F)=CN=C2Cl)=C1C#N)=O OMOUJVVCKGCADV-UHFFFAOYSA-N 0.000 description 1
- MTSXLDLSHWMFEB-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1N=C(C2=CC=CC=C2)C2=CC=CC=C2)=C2F)=CC(Cl)=C2Br)=C1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1N=C(C2=CC=CC=C2)C2=CC=CC=C2)=C2F)=CC(Cl)=C2Br)=C1C#N)=O MTSXLDLSHWMFEB-UHFFFAOYSA-N 0.000 description 1
- UNXBWIVRKRRNDY-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1NC)=C2F)=CC(Cl)=C2Br)=C1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C(C(N=C1NC)=C2F)=CC(Cl)=C2Br)=C1C#N)=O UNXBWIVRKRRNDY-UHFFFAOYSA-N 0.000 description 1
- KMXFFVBMEOJVNJ-UHFFFAOYSA-N CC(C)(C)OC(NC1=NC(C(C(C(F)=C(C(C(N(CC2)CCN2C(OC(C)(C)C)=O)=C2C#N)=C3)N=C2N=C(C2=CC=CC=C2)C2=CC=CC=C2)=C3Cl)=CC=C2F)=C2S1)=O Chemical compound CC(C)(C)OC(NC1=NC(C(C(C(F)=C(C(C(N(CC2)CCN2C(OC(C)(C)C)=O)=C2C#N)=C3)N=C2N=C(C2=CC=CC=C2)C2=CC=CC=C2)=C3Cl)=CC=C2F)=C2S1)=O KMXFFVBMEOJVNJ-UHFFFAOYSA-N 0.000 description 1
- DJEDKXLCGPJKHV-UHFFFAOYSA-N CC(C)(C)OC(NC1=NC(C(C(C(OC)=C(C2=C3)N=CC(C#N)=C2N(CC2)CCN2C(OC(C)(C)C)=O)=C3Cl)=CC=C2F)=C2S1)=O Chemical compound CC(C)(C)OC(NC1=NC(C(C(C(OC)=C(C2=C3)N=CC(C#N)=C2N(CC2)CCN2C(OC(C)(C)C)=O)=C3Cl)=CC=C2F)=C2S1)=O DJEDKXLCGPJKHV-UHFFFAOYSA-N 0.000 description 1
- OSCZNFHWOIMBJS-UHFFFAOYSA-N CC(C1=CC=CC(C(C(C#N)=C(C2=CC(Cl)=C3C(C4=C5SC(N)=N4)=CC=C5F)N(CC4)CCN4C(C=C)=O)=NC2=C3F)=C1)N(C)C Chemical compound CC(C1=CC=CC(C(C(C#N)=C(C2=CC(Cl)=C3C(C4=C5SC(N)=N4)=CC=C5F)N(CC4)CCN4C(C=C)=O)=NC2=C3F)=C1)N(C)C OSCZNFHWOIMBJS-UHFFFAOYSA-N 0.000 description 1
- ODRTUZWOXPJJFD-UHFFFAOYSA-N CN(C)C(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F Chemical compound CN(C)C(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F ODRTUZWOXPJJFD-UHFFFAOYSA-N 0.000 description 1
- JSCDUAGDLDCPOQ-UHFFFAOYSA-N CN(C)CCN1N=CC=C1C(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F Chemical compound CN(C)CCN1N=CC=C1C(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F JSCDUAGDLDCPOQ-UHFFFAOYSA-N 0.000 description 1
- LQOLVKIDUKWFCN-NHCUHLMSSA-N CN(C[C@H]1OC)C[C@H]1OC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F Chemical compound CN(C[C@H]1OC)C[C@H]1OC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F LQOLVKIDUKWFCN-NHCUHLMSSA-N 0.000 description 1
- MBMCZYJDRGWZNW-UHFFFAOYSA-N CN1CC2=CC=CC(B(O)O)=C2CC1 Chemical compound CN1CC2=CC=CC(B(O)O)=C2CC1 MBMCZYJDRGWZNW-UHFFFAOYSA-N 0.000 description 1
- MYOICFOFOZWKNM-UHFFFAOYSA-N CN1N=CC=C1C(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F Chemical compound CN1N=CC=C1C(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F MYOICFOFOZWKNM-UHFFFAOYSA-N 0.000 description 1
- JKSJRZACPWWZSB-UHFFFAOYSA-N COC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F Chemical compound COC(C(C#N)=C(C1=CC(Cl)=C2C(C3=C4SC(N)=N3)=CC=C4F)N(CC3)CCN3C(C=C)=O)=NC1=C2F JKSJRZACPWWZSB-UHFFFAOYSA-N 0.000 description 1
- DENFKTJVOUEIIA-UHFFFAOYSA-N COC(C(C=C(C(Br)=C1F)Cl)=C1NC(CC#N)=O)=O Chemical compound COC(C(C=C(C(Br)=C1F)Cl)=C1NC(CC#N)=O)=O DENFKTJVOUEIIA-UHFFFAOYSA-N 0.000 description 1
- USOFZONQDGXFSK-UHFFFAOYSA-N COC1=CC=C(CNC2=NC3=C(B(O)O)C=CC(F)=C3C=C2)C=C1 Chemical compound COC1=CC=C(CNC2=NC3=C(B(O)O)C=CC(F)=C3C=C2)C=C1 USOFZONQDGXFSK-UHFFFAOYSA-N 0.000 description 1
- YEYLJJDPMPQDEA-GOSISDBHSA-N C[C@H](CN(CC1)C(C2=CC(Cl)=C(C(C3=C4SC(N)=N3)=CC=C4F)C(F)=C2N=C2C3=CC(CN(C)C)=CC=C3)=C2C#N)N1C(C=C)=O Chemical compound C[C@H](CN(CC1)C(C2=CC(Cl)=C(C(C3=C4SC(N)=N3)=CC=C4F)C(F)=C2N=C2C3=CC(CN(C)C)=CC=C3)=C2C#N)N1C(C=C)=O YEYLJJDPMPQDEA-GOSISDBHSA-N 0.000 description 1
- SNVDXBRDNSEXSC-QGZVFWFLSA-N C[C@H](CN(CC1)C(C2=CC(Cl)=C(C(C3=C4SC(N)=N3)=CC=C4F)C(F)=C2N=C2C3=CC=NN3CCN(C)C)=C2C#N)N1C(C=C)=O Chemical compound C[C@H](CN(CC1)C(C2=CC(Cl)=C(C(C3=C4SC(N)=N3)=CC=C4F)C(F)=C2N=C2C3=CC=NN3CCN(C)C)=C2C#N)N1C(C=C)=O SNVDXBRDNSEXSC-QGZVFWFLSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 208000006104 Cytochrome P-450 CYP1A2 Inhibitors Diseases 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 208000005487 Cytochrome P-450 CYP2C9 Inhibitors Diseases 0.000 description 1
- 208000007220 Cytochrome P-450 CYP2D6 Inhibitors Diseases 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241001077419 Damas Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101150012162 H-RAS gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YXVYGOGQAFUKFU-UHFFFAOYSA-N N#CC(C(Cl)=NC1=C2F)=C(C3CCNCC3)C1=CN=C2Cl Chemical compound N#CC(C(Cl)=NC1=C2F)=C(C3CCNCC3)C1=CN=C2Cl YXVYGOGQAFUKFU-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- XDPIAISYKPAKBO-UHFFFAOYSA-N NC1=NC(C(C(C(Cl)=CC(C2=NC=C3C#N)=C3N3CCNCC3)=C2F)=CC=C2F)=C2S1 Chemical compound NC1=NC(C(C(C(Cl)=CC(C2=NC=C3C#N)=C3N3CCNCC3)=C2F)=CC=C2F)=C2S1 XDPIAISYKPAKBO-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XRIVZJXRWBPLJM-UHFFFAOYSA-N [2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-benzothiazol-4-yl]boronic acid Chemical group C(C)(C)(C)OC(=O)NC=1SC2=C(N=1)C(=CC=C2)B(O)O XRIVZJXRWBPLJM-UHFFFAOYSA-N 0.000 description 1
- MGLNHFNWYLMGHC-UHFFFAOYSA-N [3-[1-(dimethylamino)ethyl]phenyl]boronic acid Chemical compound CN(C)C(C)C1=CC=CC(B(O)O)=C1 MGLNHFNWYLMGHC-UHFFFAOYSA-N 0.000 description 1
- DPOVEZGQWNNGBG-UHFFFAOYSA-N [5-fluoro-2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-benzothiazol-4-yl]boronic acid Chemical compound CC(C)(C)OC(NC1=NC(C(B(O)O)=C(C=C2)F)=C2S1)=O DPOVEZGQWNNGBG-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 1
- QSKMFYCQRQLYMF-ZDUSSCGKSA-N benzyl (2S)-2-(cyanomethyl)piperazine-1-carboxylate Chemical group C(#N)C[C@@H]1N(CCNC1)C(=O)OCC1=CC=CC=C1 QSKMFYCQRQLYMF-ZDUSSCGKSA-N 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229930008407 benzylideneacetone Natural products 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- BYIJYBRHUZZBLR-UHFFFAOYSA-N ethyl 4-amino-6-chloro-5-fluoropyridine-3-carboxylate Chemical compound NC1=C(C=NC(=C1F)Cl)C(=O)OCC BYIJYBRHUZZBLR-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000011773 genetically engineered mouse model Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- PQWQQQGKMHENOC-UHFFFAOYSA-N imidazo[1,2-c]pyrimidine Chemical compound C1=NC=CC2=NC=CN21 PQWQQQGKMHENOC-UHFFFAOYSA-N 0.000 description 1
- JMANUKZDKDKBJP-UHFFFAOYSA-N imidazo[1,5-a]pyridine Chemical compound C1=CC=CC2=CN=CN21 JMANUKZDKDKBJP-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N iso-pentane Natural products CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- VLCMRTMCMQJSKM-UHFFFAOYSA-N phenyl-[4-phenyl-8-(trifluoromethyl)quinolin-3-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)C1=CN=C2C(C(F)(F)F)=CC=CC2=C1C1=CC=CC=C1 VLCMRTMCMQJSKM-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- FQOBINBWTPHVEO-UHFFFAOYSA-N pyrazino[2,3-b]pyrazine Chemical compound N1=CC=NC2=NC=CN=C21 FQOBINBWTPHVEO-UHFFFAOYSA-N 0.000 description 1
- JVANLUCASVHWEW-UHFFFAOYSA-N pyridazine Chemical compound N1=C=C=C=C=N1 JVANLUCASVHWEW-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- TYLGVQVJCVFREB-UHFFFAOYSA-N pyrido[3,4-b]pyrazine Chemical compound C1=NC=CC2=NC=CN=C21 TYLGVQVJCVFREB-UHFFFAOYSA-N 0.000 description 1
- PAQYIEZTLSDLQO-UHFFFAOYSA-N pyrido[3,4-d]pyrimidine Chemical compound N1=CN=C2C=NC=CC2=C1 PAQYIEZTLSDLQO-UHFFFAOYSA-N 0.000 description 1
- PLZDHJUUEGCXJH-UHFFFAOYSA-N pyrido[4,3-d]pyrimidine Chemical compound C1=NC=C2C=NC=CC2=N1 PLZDHJUUEGCXJH-UHFFFAOYSA-N 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 102000001378 ras Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 108010080092 ras Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- QWCJHSGMANYXCW-UHFFFAOYSA-N sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 description 1
- 229960004818 sulfaphenazole Drugs 0.000 description 1
- 229950003013 sulfapyrazole Drugs 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LHDKFDAHNHSESQ-MRXNPFEDSA-N tert-butyl (2R)-4-[6-chloro-3-cyano-8-fluoro-7-[7-fluoro-2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-benzothiazol-4-yl]quinolin-4-yl]-2-methylpiperazine-1-carboxylate Chemical compound C[C@H](CN(CC1)C(C2=CC(Cl)=C(C(C3=C4SC(NC(OC(C)(C)C)=O)=N3)=CC=C4F)C(F)=C2N=C2)=C2C#N)N1C(OC(C)(C)C)=O LHDKFDAHNHSESQ-MRXNPFEDSA-N 0.000 description 1
- LVIVKTJJHKPUNT-UHFFFAOYSA-N tert-butyl 4-(7-bromo-6-chloro-3-cyano-8-fluoroquinolin-4-yl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CC1)C1=C(C=NC2=C(F)C(Br)=C(Cl)C=C12)C#N LVIVKTJJHKPUNT-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- BWHOZHOGCMHOBV-BQYQJAHWSA-N trans-benzylideneacetone Chemical compound CC(=O)\C=C\C1=CC=CC=C1 BWHOZHOGCMHOBV-BQYQJAHWSA-N 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- Ras the rat sarcoma oncogene homolog
- Ras represents a group of closely related monomeric globular proteins belonging to the GTPases protein family.
- Ras is activated by growth factors and various other extracellular signals, and is responsible for regulating functions such as cell growth, survival, migration, and differentiation.
- These regulatory functions of Ras are carried out by switching between the GDP-bound state and the GTP-bound state, a "molecular switch" (Alamgeer et al., Current Opin Pharmacol. 2013, 13:394-401).
- Ras bound to GDP is an inactive form, in a dormant or off state, when the signaling system is turned off, and is activated when it is exposed to some growth-promoting stimuli, such as it can be induced by guanine nucleotide exchange factor (GEF).
- GEF guanine nucleotide exchange factor
- GDP is released and combined with GTP, the result is that Ras is "turned on” and converted into the active form of Ras, which recruits and activates various downstream effectors, carries out signal transmission, and can transmit cell surface signals to the cytoplasm, thereby Controls numerous key cellular processes such as differentiation, survival and proliferation (Zhi Tan et al., Mini-Reviews in Medicinal Chemistry, 2016, 16, 345-357).
- Ras tumor protein is a very attractive anticancer drug target widely accepted in the pharmaceutical field.
- Ras has long been regarded as an "undruggable" target in the industry.
- the present inventors have found through research that the compounds of formula (I) as defined herein, isomers thereof or their pharmaceutically acceptable salts or solvates are effective Ras mutant, especially KRas mutant protein inhibitors, capable of inhibiting cellular Ras mutations in Ras, especially KRas activity, can be used for the treatment or prevention of diseases or disorders mediated by or benefited from Ras mutations, especially KRas muteins, especially by inhibiting Ras mutations, especially KRas muteins. KRas mutant protein to inhibit abnormal cell proliferation, thereby treating or preventing tumors or cancer.
- a first aspect of the present invention provides a compound of formula (I), an isomer thereof or a pharmaceutically acceptable salt or solvate thereof,
- R b is at each occurrence independently selected from H, halogen, CN or C 1-6 alkyl optionally substituted with halogen or CN;
- E is selected from halogen, -OR d or -N(R d ) 2 -, wherein R d is each independently H or C 1-6 alkyl optionally substituted with halogen;
- R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , A, R b each have the meaning given above for the compounds of formula (I).
- a second aspect of the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I) or formula (II) of the present invention, an isomer thereof or a pharmaceutically acceptable salt or solvate thereof.
- a fifth aspect of the present invention provides a compound of formula (I) or formula (II), an isomer thereof or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same of the present invention in the manufacture of a therapeutic and Use in a medicament for the prevention of diseases mediated by Ras mutations, especially KRas mutations, preferably KRas G12C, KRas G12D or KRas G13D mutations, most preferably KRas G12C mutations.
- a sixth aspect of the present invention provides methods of treating and/or preventing diseases mediated by Ras mutations, especially KRas mutations, preferably KRas G12C, KRas G12D or KRas G13D mutations, most preferably KRas G12C mutations, comprising administering to a subject in need thereof A therapeutically effective amount of a compound of formula (I) or formula (II) of the present invention, an isomer thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the same.
- a seventh aspect of the present invention provides a process for the preparation of a compound of formula (I) or formula (II) of the present invention, an isomer thereof or a pharmaceutically acceptable salt or solvate thereof.
- An eighth aspect of the present invention provides a pharmaceutical combination comprising a compound of formula (I) or formula (II) of the present invention, an isomer thereof or a pharmaceutically acceptable salt or solvate thereof and one or more other drugs active agent.
- Ras mutant or “Ras mutein” as used herein refers to a protein encoded and expressed by a Ras gene in which one or more codons are mutated, typically including, but not limited to, glycine at codon 12 of Ras, Ras proteins with mutated glycine at codon 13 or glutamine at codon 61, such as mutated HRas, NRas or KRas. These residues are located in the active site of Ras, and their mutation can impair the intrinsic or GAP-catalyzed GTPase activity of Ras, resulting in the persistence of GTP-bound Ras.
- Ras mutant or “Ras mutein” are used interchangeably and generally refer to a mutated HRas, NRas or KRas, such as, but not limited to, HRas-G12C (glycine at codon G12 to half Mutation of cystine), NRas-G12C, KRas-G12C, KRas-G12D (mutation of glycine to aspartate at codon G12), KRas-G13D (mutation of glycine to aspartate at codon G13) ; particularly refers to KRas muteins, more particularly to KRas-G12C muteins, KRas-G12D muteins, KRas-G13D muteins, most particularly to KRas-G12C muteins.
- HRas-G12C glycine at codon G12 to half Mutation of cystine
- NRas-G12C glycine at
- treating refers to the administration of one or more compounds of formula (I) as described herein, to a subject, eg, a mammal, eg, a human, having the disease, or a symptom of the disease. Isomers thereof or their pharmaceutically acceptable salts or solvates for curing, alleviating, alleviating or affecting the disease or symptoms of the disease.
- the disease is a Ras mutation mediated disease, in particular a tumor or cancer, as defined below.
- prevention as used herein is well known in the art and is administered to a subject, eg a mammal, suspected of suffering from or susceptible to a Ras mutation-mediated disease, especially cancer or tumor, as defined herein,
- a subject eg a mammal
- administration to a human of one or more compounds of formula (I) described herein, isomers thereof, or pharmaceutically acceptable salts or solvates thereof results in a reduced risk of developing a defined disease.
- prevention encompasses the use of the compounds of the present invention prior to the diagnosis or determination of any clinical and/or pathological symptoms.
- inhibitor and “reduce”, or any variants of these terms, as used herein, refer to the ability of a biologically active agent, by directly or indirectly interacting with the target, to reduce the signaling activity of a target of interest, and refer to Any measurable reduction or complete inhibition of the activity of the target of interest.
- the activity eg, KRas activity
- the activity can be reduced by an amount of about, at most about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, as compared to normal %, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more, or any range derivable therefrom.
- selective inhibition refers to the ability of a biologically active agent to preferentially reduce the signaling activity of a target of interest over off-target signaling activity by interacting directly or indirectly with the target.
- the compound of formula (I) of the present invention has the ability to selectively inhibit G12 or G13 mutation of KRas, HRas or NRas protein relative to various mutations in one or more codons of Ras protein, such as G12C mutation , G12D mutation and G13D mutation, preferably the ability to selectively inhibit the G12C mutation of the KRas protein.
- the invention has at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% for a specific Ras mutation compared to another specific Ras mutation , 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more, or any range of better activity from which it can be derived, or with At least 1-, 2-, 3-, 4-, 5-, 10-, 25-, 50-, 100- for a specific Ras mutation (eg KRas-G12C) compared to activity against another specific Ras mutation , 250- or 500-fold better activity.
- a specific Ras mutation eg KRas-G12C
- Ras mutation-mediated disease refers to a disease in which Ras mutation contributes to the occurrence and progression of the disease, or in which inhibition of Ras mutation will reduce the incidence, reduce or eliminate disease symptoms.
- Ras mutation mediated disease preferably refers to a KRas mutation mediated disease, most preferably a KRas-G12C mediated disease, still more preferably cancer or tumor.
- the term “cancer” or “tumor” refers to abnormal cell growth and proliferation, whether malignant or benign, and all precancerous cells and cancer cells and tissues.
- the cancer or tumor includes, but is not limited to, lung adenocarcinoma, lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer cancer, anal region cancer, stomach cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small bowel cancer, endocrine system cancer, thyroid cancer, Parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal cell cancer, renal pelvis cancer, central
- the cancer or tumor is associated with a Ras mutation, especially a KRas mutation, preferably a KRas G12C, KRas G12D or KRas G13D mutation, most preferably a KRas G12C mutation, including but not limited to the tumor types described above and their Preferred range.
- a KRas mutation preferably a KRas G12C, KRas G12D or KRas G13D mutation, most preferably a KRas G12C mutation, including but not limited to the tumor types described above and their Preferred range.
- Particularly preferred tumors of the present invention include lung cancer, lung adenocarcinoma, colon cancer, rectal cancer, pancreatic cancer, endometrial cancer, bile duct cancer, leukemia and ovarian cancer.
- the terms "subject”, “individual” or “patient” as used herein refer to vertebrates.
- the vertebrate is a mammal.
- Mammals include, but are not limited to, farm animals (eg, cattle), sport animals, pets (eg, guinea pigs, cats, dogs, rabbits, and horses), primates, mice, and rats.
- the mammal is a human.
- the term "therapeutically effective amount” refers to an amount or dosage that is generally sufficient to produce a beneficial therapeutic effect in a patient with a cancer or tumor in need of treatment. Those skilled in the art can determine the effective amount or dosage of the active ingredient in the present invention by conventional methods and in combination with conventional influencing factors.
- pharmaceutical combination means that a compound of the present invention may be used in combination with other active agents for the purposes of the present invention.
- the other active agent may be one or more additional compounds of the present invention, or may be a second or additional (eg, third) compound that is compatible with, that is, does not adversely affect each other, or has complementary activities.
- compounds such as these active agents are known to modulate other biologically active pathways, or to modulate different components of the biologically active pathways involved in the compounds of the invention, or even to overlap with the biological targets of the compounds of the invention.
- Such active agents are suitably combined in amounts effective to achieve the intended purpose.
- the other active agents may be co-administered with the compound of the present invention in a single pharmaceutical composition, or administered separately from the compound of the present invention in separate discrete units, either simultaneously or sequentially when administered separately.
- the sequential administrations may be close or distant in time.
- other active agents that can be used in combination with the compounds of the present invention include, but are not limited to, chemotherapeutic agents, therapeutic antibodies, and radiation therapy, such as alkylating agents, antimetabolites, cell cycle inhibitors, mitotic inhibitors, topoisomerase inhibitors agents, antihormonal drugs, angiogenesis inhibitors or cytotoxic agents.
- pharmaceutically acceptable means molecular entities and compositions that do not produce adverse, allergic or other untoward reactions when administered in appropriate amounts to animals such as humans.
- the term “pharmaceutically acceptable salts” refers to those salts, including acid addition salts and base addition salts, that retain the biological effectiveness and properties of the parent compound and are not biologically or otherwise undesirable.
- “Pharmaceutically acceptable acid addition salts” can be formed from compounds having free bases with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, etc.
- the organic acid can be selected from aliphatic , cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic organic acids, such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, Maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, pamoic acid, Phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc.
- organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid,
- “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like, as well as those derived from pharmaceutically acceptable bases.
- organic non-toxic bases including but not limited to primary, secondary and tertiary amines, substituted ammonium including naturally occurring substituted amines, cyclic amines and basic ion exchange resins such as ammonia, isopropylamine, trimethylamine, Diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, tromethamine, dicyclohexylamine, lysine, arginine, histamine Acid, Caffeine, Procaine, Hebamine, Choline, Betaine, Ethylenediamine, Glucosamine, Methylglucamine, Triethanolamine, Theobromine, Purine, Piperazine, Piperidine, N- Ethyl piperidine, polyamine resin, etc.
- basic ion exchange resins such as ammonia, isopropylamine, trimethylamine, Diethylamine, trieth
- isomer refers to any stereoisomer, enantiomeric mixture, including racemates, diastereomeric mixtures, geometric isomers, enantiomeric mixtures, which may exist in a compound in structure Isomers and/or tautomers. Methods for the determination and separation of the stereochemistry of such isomers are well known to those skilled in the art (S.P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E.
- R and S represent the absolute configuration of the chiral center, and the determination of the absolute configuration is this well known to those skilled in the art.
- solvate refers to a solvent addition form comprising a stoichiometric or non-stoichiometric amount of solvent, including any solvated form of a compound of the present invention, including, for example, a solvate with water, such as a hydrate, or a solvate with an organic solvent such as methanol, ethanol or acetonitrile, ie as methanolate, ethanolate or acetonitrile, respectively; or in the form of any polymorph. It should be understood that such solvates of the compounds of the present invention also include solvates of pharmaceutically acceptable salts of the compounds of the present invention.
- isotopic variant refers to a compound that contains an unnatural proportion of isotopes at one or more of the atoms that make up the compound.
- the compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms constituting the compounds, thereby forming isotopic variations of the compounds of the present invention or pharmaceutically acceptable salts thereof, whether radioactive or not, are intended to are encompassed within the scope of the present invention.
- isotopes and pharmaceutically acceptable salts thereof that may be incorporated into the compounds of the present invention include, for example, 2 H, 3 H, 13 C, 14 C, 15 N, 17 O, 18 O, 31 P, 32 P, 35 S , 18 F and 36 Cl.
- isotopic variations of the compounds of the present invention and their pharmaceutically acceptable salts can generally be prepared by conventional methods using appropriate isotopic variations of suitable reagents.
- Certain isotopic variations of the compounds of the invention, and pharmaceutically acceptable salts thereof, such as those into which radioactive isotopes (eg, 3 H or 14 C) are incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated, ie, 3H , and carbon- 14 , or14C, isotopes are particularly preferred due to ease of preparation and detectability.
- substitution with isotopes such as deuterium, ie, 2 H may provide certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and is therefore preferred in certain circumstances.
- compounds of the invention substituted with positron emitting isotopes eg 11 C, 18 F, 15 O and 13 N
- PET positron tomography
- metabolite means a product produced by metabolism of a particular compound in vivo. Such products may, for example, result from oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, and the like, of the administered compound. Identification and analysis of metabolite products is performed in a manner well known to those skilled in the art.
- prodrug refers to a compound that can be converted under physiological conditions or by solvolysis to a biologically active compound described herein, eg, a compound of formula (I).
- prodrug refers to a precursor of a pharmaceutically acceptable biologically active compound.
- the prodrug is inactive when administered to a subject, but is converted to the active compound in vivo, eg, by hydrolysis.
- Prodrug compounds generally offer the advantages of solubility, histocompatibility or delayed release in mammalian organisms (see, eg, Bundgard, H., Design of Prodrugs (1985), pp. 7-9, pp. 21-24 (Elsevier , Amsterdam).
- prodrugs can be found in Higuchi, T. et al., ACS Symposium Series, Vol. 14, and "Bioreversible Carriers in Drug Design", Edward B. Roche, USA Pharmaceutical Association & Pergamon Press, 1987, which is incorporated herein by reference in its entirety.
- the term "prodrug” is also meant to include any covalently bonded carrier that is released in vivo when such prodrug is administered to a mammalian subject Active compounds.
- Prodrugs of active compounds as described herein are generally prepared by modifying functional groups present in the active compound so that the modification can be cleaved to the parent active compound in routine practice or in vivo.
- Prodrugs include such Compounds in which a hydroxy, amino or sulfhydryl group is bonded to any group that cleaves to form a free hydroxy, free amino or free sulfhydryl group when the prodrug is administered to a mammal.
- Examples of prodrugs include, but are not limited to, hydroxy functional acetate esters , formate and benzoate derivatives, or acetamide, formamide, and benzamide derivatives of the amine functional group in the active compound.
- prodrugs include phosphate-containing prodrugs, boronate ester prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, Prodrugs of beta-lactam, optionally substituted phenoxyacetamide-containing prodrugs, or optionally substituted phenylacetamide-containing prodrugs, and 5-fluorocytosine and 5-fluorouridine prodrugs.
- pharmaceutically acceptable excipient or carrier refers to one or more compatible solid or liquid filler or gelling substances, suitable for human use, of sufficient purity and sufficiently low toxicity , whose examples include but are not limited to cellulose and its derivatives (such as sodium carboxymethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as magnesium stearate), calcium sulfate, vegetable oils, polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (such as Tween), wetting agents (such as sodium lauryl sulfate), colorants, flavors, stabilizers, antioxidants, preservatives Wait.
- cellulose and its derivatives such as sodium carboxymethyl cellulose, cellulose acetate, etc.
- gelatin talc
- solid lubricants such as magnesium stearate
- calcium sulfate such as magnesium stearate
- vegetable oils such as prop
- halogen or "halo” as used herein means F, Cl, Br or I.
- halogen-substituted group is intended to include mono- or polyhalogenated groups in which one or more of the same or different halogens replace one or more hydrogens in the group.
- alkyl refers to a straight or branched chain saturated hydrocarbon group consisting of carbon atoms and hydrogen atoms. Specifically, the alkyl group has 1 to 10, eg, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2 carbon atoms.
- Ci - C6 alkyl refers to a straight or branched chain saturated hydrocarbon group having 1 to 6 carbon atoms, examples of which are methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl or tert-butyl), pentyl (including n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, etc.
- Particular alkyl groups have 1 to 3 carbon atoms.
- alkoxy means the group -O-alkyl, wherein alkyl has the meaning set forth herein. Specifically, the term includes the groups -OC 1-6 alkyl, more specifically -OC 1-3 alkyl. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy, isopropoxy), butoxy (including n-butoxy, isobutoxy, tert-butoxy), pentyloxy (including n-pentyloxy, isopentyloxy, neopentyloxy), hexyloxy (including n-hexyloxy, isohexyloxy) and the like. Particular alkoxy groups have 1 to 3 carbon atoms.
- alkylthio refers to an -S-alkyl group, wherein the alkyl group is as defined above for "alkyl”. Specifically, the term includes the groups -SC 1-6 alkyl, more specifically -SC 1-3 alkyl.
- alkylthio include, but are not limited to, methylthio, ethylthio, propylthio (including n-propylthio, isopropylthio), butylthio (including n-butylthio, isobutylthio, tert-butylthio), pentylthio (including n-pentylthio, isopentylthio, neopentylthio), hexylthio (including n-hexylthio, isohexylthio) and the like.
- Particular alkylthio groups have 1 to 3 carbon atoms.
- halogen-substituted C1 - C6 alkyl refers to the C1 - C6 alkyl groups described above, wherein one or more (eg 1, 2, 3, 4 or 5) ) hydrogen atoms are replaced by halogens. It will be understood by those skilled in the art that when there is more than one halogen substituent, the halogens may be the same or different, and may be located on the same or different C atoms.
- halogen substituted C1 - C6 alkyl are eg -CH2F , -CHF2 , -CF3 , -CCl3 , -C2F5 , -C2Cl5 , -CH2CF3 , -CH 2 Cl, -CH 2 CH 2 CF 3 or -CF(CF 3 ) 2 , etc.
- cycloalkyl refers to a monocyclic, fused polycyclic, bridged polycyclic or spirocyclic non-aromatic saturated monovalent hydrocarbon ring structure having the specified number of ring atoms. Cycloalkyl groups may have 3 to 12 carbon atoms (ie C3 - C12 cycloalkyl), eg 3 to 10, 3 to 8, 3 to 7, 3 to 6, 5 to 6 carbon atoms .
- Suitable cycloalkyl groups include, but are not limited to, monocyclic structures, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; or polycyclic (eg, bicyclic) structures, including spiro Ring, fused or bridged systems such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, spiro[3.4]octyl, bicyclo[3.1.1]hexyl, bicyclo[3.1. 1] Heptyl or bicyclo[3.2.1] octyl and the like.
- monocyclic structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl
- polycyclic (eg, bicyclic) structures including spiro Ring,
- cycloalkenyl means a monocyclic, fused polycyclic, bridged polycyclic, or spirocyclic non-aromatic unsaturated hydrocarbon ring structure having the specified number of ring atoms, comprising at least one (eg, 1, 2, or 3) carbon-carbon double bonds.
- Cycloalkenyl groups may have 3 to 12 carbon atoms (ie, C3 - C12 cycloalkenyl groups), such as 3 to 10, 3 to 8, 3 to 7, 3 to 6, 5 to 6 carbon atoms .
- Suitable cycloalkenyl groups include, but are not limited to, monocyclic structures such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptene cycloheptadienyl, cycloheptatrienyl, or cyclooctenyl.
- heterocycloalkyl as used herein means a monocyclic, fused, monocyclic, fused ring comprising one or more (eg 1, 2, 3 or 4) heteroatoms independently selected from O, N and S and the specified number of ring atoms
- Heterocycloalkyl may have 3 to 12 ring members (may be referred to as 3-12 membered heterocycloalkyl), for example 3 to 10 ring members, 3 to 8 ring members, 3 to 7 ring members, 4 to 7 ring members, 4 to 6 ring members, 5 to 6 ring members.
- Heterocycloalkyl groups typically contain up to 4 (eg, 1, 2, 3, or 4) heteroatoms. Examples of suitable heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl (eg, 1-pyrrolidinyl, 2-pyrrolidinyl, and 3-pyrrolidinyl).
- -pyrrolidinyl tetrahydrofuranyl (eg 1-tetrahydrofuranyl, 2-tetrahydrofuranyl and 3-tetrahydrofuranyl), tetrahydrothienyl (eg 1-tetrahydrothienyl, 2-tetrahydrothienyl and 3-tetrahydrothienyl) thienyl), piperidinyl (such as 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), tetrahydropyranyl (such as 4-tetrahydropyranyl), Tetrahydrothiopyranyl (eg 4-tetrahydrothiopyranyl), morpholinyl (eg morpholino), thiomorpholinyl, dioxanyl, piperazinyl or azepanyl, diazepine Cycloheptyl groups such as 1,4-diazacycloheptyl, 3,6-
- heterocycloalkyl groups such as It should be understood that structures having an asymmetric center encompass their racemic and/or single enantiomeric forms, such as representable and / or
- an optionally substituted group as used herein, unless otherwise indicated, means that a group may be unsubstituted or be derivatized by one or more (eg, 0, 1, 2, 3, 4, or 5 or more), or wherein derivatizable any range) for that group is substituted with the substituents listed for that group, wherein the substituents may be the same or different.
- an optionally substituted group has 1 substituent.
- an optionally substituted group has 2 substituents.
- an optionally substituted group has 3 substituents.
- an optionally substituted group has 4 substituents.
- an optionally substituted group has 5 substituents.
- the present invention also covers N-oxides of compounds of formula (I) or formula (II), provided that these compounds contain basic nitrogen atoms, such as those present in nitrogen-containing heterocycles. Certain compounds of the present invention may exist in polymorphic or amorphous forms and are therefore also within the scope of the present invention.
- X is selected from a bond, -O- or -NH-;
- A is N.
- A is CR a , wherein R a is F or Cl, preferably Cl.
- R1 is selected from H or halogen.
- both R2 and R3 are H.
- Rb is H.
- R and R is C1-6 alkyl , preferably C1-3 alkyl, substituted by CN; in specific embodiments, there is one R b and R b is cyanomethyl; in a more specific embodiment, there is one R b and R b is cyanomethyl, and the attachment on the piperazine ring is
- -XR4 is not H.
- -XR4 is halogen; in specific embodiments, -XR4 is Cl or F.
- -XR 4 is -C 0-6 alkyl-phenyl, preferably -C 0-3 alkyl-phenyl, more preferably phenyl having The meanings given above for the embodiments, preferred or more preferred embodiments of phenyl as R 4 .
- -XR 4 is -OC 0-6 alkyl-phenyl, preferably -OC 0-3 alkyl-phenyl, more preferably -O-phenyl, wherein benzene Radical has the meanings given above for the embodiment, preferred or more preferred embodiment given for phenyl as R 4 .
- -XR 4 is -C 0-6 alkyl-C 3-6 cycloalkyl, preferably -C 0-3 alkyl-C 3-6 cycloalkyl, More preferred are C 3-6 cycloalkyl groups having the meanings given above for the embodiments, preferred or more preferred embodiments as cycloalkyl in R 4 .
- 1-tetrahydrofuranyl hydrothienyl, 2-tetrahydrothienyl and 3-tetrahydrothienyl), piperidinyl (such as 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), tetra Hydropyranyl (eg 4-tetrahydropyranyl), tetrahydrothiopyranyl (eg 4-tetrahydrothiopyranyl), morpholinyl (eg morpholino), thiomorpholinyl, dioxanyl or piperazinyl.
- piperidinyl such as 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl
- tetra Hydropyranyl eg 4-tetrahydropyranyl
- tetrahydrothiopyranyl tetrahydrothiopyranyl
- morpholinyl eg morpholino
- R 4 is selected from Most preferably R4 is selected from
- exemplary substituents include, but are not limited to: F, Cl , Br, I, -CH3 , -CH2CH3 , -CH2CH2CH3 , -CH ( CH3 ) CH3 , -CH2CH( CH3 ) CH3 , -CH2CH2CH2CH3 , -C ( CH3 ) ( CH3 ) ( CH3 ) , -CH2F , -CHF2 , -CF3 , -CH 2 CF 3 , -CH 2 CH 2 CF 3 , -CH(CF 3 )CH 3 , -CH 2 CH(CF 3 )CH 3 , -CH 2 CH 2 CH 2 CF 3 , -C(CF 3 ) ( CH3 )( CH3 ) , -CH2OH , -CH2CH2OH , -CH2CH2CH2OH , -CH2CH ( OH ) CH3 , -CH2CH ( OH )
- the 5-6 membered heteroaryl in R is selected from the group consisting of pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl , oxtriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl and triazinyl.
- R 4 is selected from Most preferably, R4 is selected from
- -XR4 is -C0-6alkyl -5-6 membered heteroatoms containing 1, 2 or 3 heteroatoms independently selected from N, O or S Aryl, preferably -C 0-3 alkyl - 5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O or S, more preferably 1, 2 or 3 independently 5-6 membered heteroaryl radicals selected from heteroatoms of N, O or S, said heteroaryl radicals having the meanings given above for the embodiments, preferred or more preferred embodiments given as heteroaryl in R4 .
- -XR4 is -OC0-6alkyl -5-6 membered heteroatoms containing 1, 2 or 3 heteroatoms independently selected from N, O or S Aryl, preferably -OC 0-3 alkyl - 5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O or S, more preferably 1, 2 or 3 independently 5-6 membered heteroaryl radicals selected from heteroatoms of N, O or S, said heteroaryl radicals having the meanings given above for the embodiments, preferred or more preferred embodiments given as heteroaryl in R4 .
- -XR4 is -NH- C0-6alkyl -5-6 containing 1, 2 or 3 heteroatoms independently selected from N, O or S Membered heteroaryl, preferably -NH-C 0-3 alkyl - 5-6 membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O or S, more preferably 1, 2 or 3 heteroatoms independently selected from N, O or S heteroatoms of 5-6 membered heteroaryl having the embodiments, preferred or more preferred embodiments given above for the heteroaryl as R the meaning of the way.
- -( CRcRc ) 0-6 - SRc , - ( CRcRc ) 0-6- (CO) 0-1 as substituents of R4 -OR c , -(CR c R c ) 0-6 -(CO) 0-1 -N(R c ) 2 are each preferably -(CR c R c ) 0-6 -SR c , -(CR c R c ) 0-6 -OR c , -(CR c R c ) 0-6 -N(R c ) 2 ; more preferably -(CR c R c ) 0-3 -SR c , -(CR c R c ) 0-3 -OR c , -(CR c R c ) 0-3 -N(R c ) 2 .
- E is halogen, preferably F.
- E is -OR d and R d is C 1-6 alkyl optionally substituted with halogen, preferably C 1-6 alkyl, such as but not limited to methyl, Ethyl, propyl, isopropyl, trifluoromethyl, difluoromethyl, trifluoroethyl and the like.
- R5 is Among them, at most two of Z, G, Y, B, and D are not C. Exemplary R5 includes, but is not limited to
- R 5 is Among them, at most two of Z, Y, B, and D are not C.
- Exemplary R5 includes, but is not limited to In a more preferred embodiment, R 5 is Most preferably R5 is
- R 5 is more preferred
- At least one of R6, R7 and R8 is halogen, preferably F.
- R6 is F
- R7 and R8 are H.
- At least one of R6, R7 and R8 is halogen substituted C1-6 alkyl , preferably -CF3 .
- R c is H or C 1-6 alkyl.
- the present invention also provides compounds of formula (II), isomers, pharmaceutically acceptable salts or solvates thereof.
- R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , A, E, R b each have the meaning given above for the compounds of formula (I).
- A is selected from CR a or N, wherein R a is selected from halogen;
- R 1 , R 2 and R 3 are each independently selected from H, halogen or C 1-6 alkyl;
- R b is at each occurrence independently selected from H, halogen, CN or C 1-6 alkyl optionally substituted with halogen or CN;
- X is selected from a bond, -O- or -NH-;
- R 4 is selected from H, halogen, C 1-6 alkyl, -C 0-3 alkyl-C 6-10 aryl, -C 0-3 alkyl-C 3-8 cycloalkyl, -C 0- 3 alkyl-C 3-8 cycloalkenyl, -C 0-3 alkyl - 3-8 membered heterocycloalkyl containing 1, 2 or 3 independent heteroatoms selected from N, O or S, - C 0-3 alkyl - 3-8 membered heterocycloalkenyl containing 1, 2 or 3 independent heteroatoms selected from N, O or S, -C 0-3 alkyl - containing 1, 2 or 3 5-10 membered heteroaryl independently selected from heteroatoms of N, O or S, wherein the alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl and heterocycloalkenyl Aryl is optionally substituted with 1, 2 or
- R c is independently at each occurrence selected from H or C 1-6 alkyl optionally substituted with halogen;
- E is selected from halogen, -OR d or -N(R d ) 2 -, wherein R d is each independently H or C 1-6 alkyl optionally substituted with halogen;
- R 6 , R 7 and R 8 are each independently selected from H, halogen and C 1-6 alkyl optionally substituted with halogen;
- A is CR a , wherein R a is selected from F or Cl, preferably Cl.
- R b is H.
- Rb is other than H and there is either one Rb or two Rbs present.
- -XR4 is H.
- -XR4 is not H.
- At least one of R6, R7 and R8 is halogen, preferably F ; more preferably R6 is F, and R7 and R8 are H.
- E is halogen, preferably F.
- E is -OR d and R d is C 1-6 alkyl optionally substituted with halogen, preferably C 1-6 alkyl, such as but not limited to methyl group, ethyl, propyl, isopropyltrifluoromethyl, difluoromethyl, trifluoroethyl and the like.
- R4 is selected from H, halogen, C1-6 alkyl, phenyl, C3-6 cycloalkyl, containing 1, 2 or 3 independent 4-6 membered heterocycloalkyl with heteroatoms selected from N, O or S and 5-6 membered heteroaryl containing 1, 2 or 3 independent heteroatoms selected from N, O or S, wherein the The alkyl, aryl, cycloalkyl, heterocycloalkyl and heteroaryl groups are optionally substituted with 1, 2 or 3 groups independently selected from halogen, C 1-6 optionally substituted with halogen Alkyl, -( CRcRc ) 0-6 - ORc and -( CRcRc ) 0-6 -N( Rc ) 2 where attached to aryl, cycloalkyl, cycloalkenyl, hetero -(CR c R c ) 0-6 -N(R c ) 2 on cyclo
- R4 is selected from halogen, preferably F or Cl.
- R4 is selected from C1-6 alkyl, such as methyl, ethyl, propyl, isopropyl, etc., optionally independently selected from the following 1, 2 or 3 group substitutions: halogen, C 1-6 alkyl optionally substituted with halogen, -(CR c R c ) 0-6 -OR c and -(CR c R c ) 0-6 - N(R c ) 2 .
- R 4 is selected from phenyl, optionally halogen, C 1-6 alkyl optionally substituted with halogen, -(CR c R c ) 0-6 -OR c and -(CR c R c ) 0-6 -N(R c ) 2 are substituted.
- R4 is selected from C3-6cycloalkyl , optionally substituted with 1, 2 or 3 groups independently selected from halogen, optionally Halogen-substituted C 1-6 alkyl, -(CR c R c ) 0-6 -OR c and -(CR c R c ) 0-6 -N(R c ) 2 .
- R4 is selected from 4-6 membered heterocycloalkyl containing 1, 2 or 3 independent heteroatoms selected from N, O or S, optionally Substituted with 1 , 2 or 3 groups independently selected from halogen, C 1-6 alkyl optionally substituted with halogen, -(CR c R c ) 0-6 -OR c and -(CR c R c ) 0-6 -N(R c ) 2 .
- R4 is selected from 5-6 membered heteroaryl containing 1, 2 or 3 independent heteroatoms selected from N, O or S, optionally substituted with 1, 2 or 3 groups independently selected from halogen, C 1-6 alkyl optionally substituted with halogen, -(CR c R c ) 0-6 -OR c and -(CR c R c c ) 0-6 -N(R c ) 2 .
- R c is independently selected at each occurrence from H or C 1-6 alkyl.
- the present invention also provides embodiments of compounds of formula (II) wherein each of R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , A, E, R b is of formula ( I) Meaning in the given embodiment, preferred, more preferred or most preferred embodiment of the compound.
- the compound of the present invention covers each of the above independent embodiments or specific embodiments, and also covers the above-mentioned embodiments or embodiments formed by any combination or sub-combination of specific embodiments, and also covers any of the above preferred or example embodiments Any combination of the above examples constitutes an embodiment.
- Specific embodiments of the compounds of the present invention include the following specific compounds or isomers, pharmaceutically acceptable salts or solvates thereof,
- the compounds defined herein above and various embodiments thereof are inhibitors of Ras mutations, especially KRas mutations, including mutations at codons G12, G13 and Q61, eg, G12C mutation, G12D mutation, G13D mutation.
- the compounds of the present invention especially those specifically exemplified in the context of this document, show proliferation-inhibitory activity in cellular assays against Ras-mutated, especially KRas G12C-mutated cells, as shown in the Activity Examples section below.
- the compounds of the present invention can be used for the treatment or prevention of diseases mediated by Ras mutations, preferably KRas mutations, most preferably KRas G12C mutations, such as diseases or conditions that can be treated by inhibiting Ras mutations, preferably KRas mutations, most preferably KRas G12C mutations, Or a disease or disorder in which Ras mutation, preferably KRas mutation, most preferably KRas G12C mutation activity plays a role or is implicated, in particular to treat or prevent tumors or cancer by inhibiting Ras mutation, preferably KRas mutation, most preferably KRas G12C mutation.
- some compounds of the present invention also show inhibitory activity against KRas G12D mutation, and other compounds of the present invention show inhibitory activity against KRas G13D mutation.
- the compounds as defined herein and their various embodiments, especially the example compounds have improved structural patterns compared to KRas muteins existing in the prior art, which inhibit the agent that retains comparable or enhanced, even significantly enhanced KRas mutant proteins and related cancer cell proliferation-inhibiting activity; has a different spectrum of biological activity for new indications; has improved metabolic stability, resulting in more Good pharmacokinetic properties; and improved physical and chemical properties, so that it has good druggability, such as easier absorption in the body.
- the present invention provides a compound of the present invention, an isomer thereof, or a pharmaceutically acceptable salt or solvate thereof for use as a medicament.
- the present invention provides compounds of the present invention, isomers thereof or pharmaceutically acceptable salts or solvates thereof for use in the treatment and/or prevention of diseases mediated by Ras mutations, preferably KRas mutations.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I) or formula (II) as defined above, an isomer thereof or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, diluent or excipient.
- the pharmaceutical composition of the present invention can be used for the treatment or prevention of diseases mediated by Ras mutations, especially KRas mutations, such as diseases mediated by KRas G12C, KRas G12D or KRas G13D mutations, such as tumors or cancers.
- compositions of the present invention can be formulated by techniques known to those skilled in the art, such as those disclosed in Remington's Pharmaceutical Sciences 20th Edition.
- compositions of the present invention are in accordance with good medical practice. Factors to be considered in this context include the particular disorder being treated, the particular mammal being treated, the clinical situation of the individual patient, the cause of the disorder, the location of drug delivery, the method of administration, the schedule of administration, and other factors well known to medical practitioners. Optimal dosage levels and frequency of administration of the pharmaceutical compositions of the present invention will be determined by clinical trials required in the art of pharmacy.
- daily doses for oral administration will range from about 0.001 mg to about 100 mg per kg of patient body weight, often 0.01 mg to about 50 mg per kg body weight, such as 0.1 to 10 mg per kg body weight, preferably about 0.01 to about 35 mg per kg body weight kg body weight in single or divided doses.
- a suitable dosage range is from about 0.07 to about 7000 mg/day, preferably from about 0.7 to about 2500 mg/day. It will be understood that it may be necessary in certain circumstances to use doses above these limits.
- compositions of the present invention may be administered in any suitable manner, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal, inhalation and epidural and intranasal, and if topical treatment is desired, intralesional administration can also be employed.
- Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration.
- oral administration is employed.
- compositions of the present invention may be administered in any convenient form of administration, such as tablets, powders, capsules, lozenges, granules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches Wait.
- compositions may contain conventional components in pharmaceutical formulations, such as diluents (eg, glucose, lactose or mannitol), carriers, pH adjusters, buffers, sweeteners, fillers, stabilizers, surfactants, Wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, glidants, processing aids, colorants, perfuming agents, flavoring agents, other known additives, and other active agents.
- diluents eg, glucose, lactose or mannitol
- carriers pH adjusters, buffers, sweeteners, fillers, stabilizers, surfactants, Wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, glidants, processing aids, colorants, perfuming agents, flavoring agents, other known additives, and other active agents.
- Suitable carriers and excipients are well known
- the compounds of formula (I) or formula (II) of the present invention and the compounds of various embodiments thereof, especially the compounds specifically prepared and characterized in the Examples, show resistance to Ras mutations, especially KRas mutations, For example the inhibitory effect of KRas G12C, KRas G12D or KRas G13D mutations.
- the present invention provides a method for inhibiting Ras mutation, especially KRas mutation, preferably KRas G12C, KRas G12D or KRas G13D mutation, most preferably KRas G12C mutation in a cell, comprising making the cell with the formula ( I) or a compound of formula (II), its isomers or their pharmaceutically acceptable salts or solvates are contacted to inhibit Ras mutation, especially KRas mutation, preferably KRas G12C, KRas G12D or KRas G13D mutation, most The activity of the KRas G12C mutation is preferred.
- the present invention also accordingly provides a method for inhibiting abnormal cell growth in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or formula (II) of the present invention, its isoform Constituents or their pharmaceutically acceptable salts or solvates, or pharmaceutical combinations comprising the compounds of formula (I) or (II) of the present invention, their isomers or their pharmaceutically acceptable salts or solvates thing.
- the present invention provides methods for the treatment and/or prevention of diseases mediated by Ras mutations, especially KRas mutations, preferably KRas G12C, KRas G12D or KRas G13D mutations, most preferably KRas G12C mutations, including administering a therapeutically effective amount of a compound of formula (I) or formula (II) of the present invention, an isomer thereof or a pharmaceutically acceptable salt or solvate thereof, or a compound of formula (I) or formula ( II) Pharmaceutical compositions of the compounds, their isomers or their pharmaceutically acceptable salts or solvates.
- the present invention provides a compound of formula (I) or formula (II) of the present invention, an isomer thereof or a pharmaceutically acceptable salt or solvate thereof, or a compound of formula (I) or formula comprising the present invention (II)
- a pharmaceutical composition of a compound, an isomer thereof or a pharmaceutically acceptable salt or solvate thereof for inhibiting Ras mutation, especially KRas mutation, preferably KRas G12C, KRas G12D or KRas G13D mutation in cells , most preferably the KRas G12C mutation, or for inhibiting abnormal cell growth in mammals, or for the treatment and/or prevention of mutations mediated by Ras mutations, especially KRas mutations, preferably KRas G12C, KRas G12D or KRas G13D, most preferably KRas G12C mutations induced disease.
- the present invention provides a compound of formula (I) or formula (II) of the present invention, an isomer thereof or a pharmaceutically acceptable salt or solvate thereof, or a compound of formula (I) or formula comprising the present invention (II)
- Pharmaceutical compositions of the compounds, their isomers or their pharmaceutically acceptable salts or solvates are prepared for use in the treatment and/or prophylaxis of mutations caused by Ras, especially KRas mutations, preferably KRas G12C, KRas G12D or KRas Use in the medicament of a disease mediated by a G13D mutation, most preferably a KRas G12C mutation.
- the abnormal cell growth or the disease mediated by Ras mutation especially KRas mutation, preferably KRas G12C, KRas G12D or KRas G13D, most preferably KRas G12C mutation, especially refers to of cancer or tumor.
- Exemplary such cancers or tumors include, but are not limited to, lung cancer, lung adenocarcinoma, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, anal region cancer , gastric cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small bowel cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, Adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvis cancer, central nervous system tumor (CNS), primary CNS lymphoma, spinal tumor, brainstem glioma, or pituitary adenoma.
- CNS central nervous
- the abnormal cell growth or the disease mediated by Ras mutation is preferably selected from lung adenocarcinoma, lung cancer. , colon cancer, rectal cancer, pancreatic cancer, bile duct cancer, endometrial cancer, ovarian cancer, leukemia; most preferably selected from lung adenocarcinoma, colon cancer, rectal cancer, pancreatic cancer, bile duct cancer.
- the present invention provides the above-mentioned various methods and uses for the treatment or prevention of cancer or tumor by inhibiting the KRas-G12C mutation.
- the present invention provides the above-mentioned methods and technical solutions for the treatment or prevention of lung adenocarcinoma, colon cancer, rectal cancer, pancreatic cancer and bile duct cancer by inhibiting KRas-G12C mutation.
- the other active agent may be one or more additional compounds of the present invention, or may be a second or additional (eg, third) compound that is compatible with, that is, does not adversely affect each other, or has complementary activities.
- these active agents may be compounds known to modulate other biologically active pathways, or may be compounds that modulate different components of the biologically active pathways involved in the compounds of the invention, or even biological targets related to the compounds of the invention overlapping compounds.
- the compounds of the present invention and other active agents may be (i) prior to sending the combination product to a physician (eg, in the case of a kit comprising a compound of the present invention and an additional drug); (ii) immediately prior to administration by The physician himself (or under the direction of the physician); (iii) by the patient himself, eg, during sequential administration of the compound of the invention and the other active agent together into the combination therapy.
- a physician eg, in the case of a kit comprising a compound of the present invention and an additional drug
- immediately prior to administration by The physician himself (or under the direction of the physician) or by the patient himself, eg, during sequential administration of the compound of the invention and the other active agent together into the combination therapy.
- the abnormal cell growth involved therein or is caused by Ras mutation, especially KRas mutation, preferably KRas G12C, KRas G12D or KRas G13D, most preferably KRas G12C Mutation-mediated diseases are as defined above for the methods and uses of the invention.
- Step D tert-Butyl (4-bromo-7-fluorobenzo[d]thiazol-2-yl)carbamate
- intermediate Int B2 The synthesis of intermediate Int B2 was carried out as described in intermediate Int B1, substituting (R)-2-methylpiperazine-1-carboxylate tert-butyl ester with piperazine-1-carboxylate tert-butyl ester. LCMS (m/z): 503.2 (M+H).
- intermediate Int C2 The synthesis of intermediate Int C2 was carried out as described in Intermediate Int C1 using 4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinolin-4-yl)piperazine-1 - tert-butyl carboxylate (Intermediate B2) in place of (R)-4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinolin-4-yl)-2-methyl Piperazine-1-carboxylate tert-butyl ester (Intermediate B1). LCMS (m/z): 459.2, 471.2 (M+H).
- Step B 4-Amino-6-chloro-5-fluoronicotinic acid ethyl ester
- Step C 6-Chloro-4-(2-cyanoacetamido)-5-fluoronicotinic acid ethyl ester
- Step D 7-Chloro-8-fluoro-2,4-dihydroxy-1,6-naphthyridine-3-carbonitrile
- 6-Chloro-4-(2-cyanoacetamido)-5-fluoronicotinic acid ethyl ester 300 mg, 1.05 mmol was dissolved in THF (10 mL) and stirred under an ice bath for 2 min, followed by tert-butanol Potassium (236 mg, 2.10 mmol) was slowly added to the reaction solution. Under the condition that the ice bath naturally returned to room temperature, the mixture was stirred for 1 h. After the reaction was detected by LCMS, the reaction was added dropwise to a stirred saturated NH 4 Cl (50 mL) solution, and the pH of the mixed solution was adjusted to 7 with 1N hydrochloric acid.
- Step E 2,4,7-Trichloro-8-fluoro-1,6-naphthyridine-3-carbonitrile
- intermediate Int E1 The synthesis of intermediate Int E1 was carried out as described in intermediate Int B1, substituting 2,4,7-trichloro-8-fluoro-1,6-naphthyridine-3-carbonitrile (intermediate Int D) for 7- Bromo-2,4,6-trichloro-8-fluoroquinoline-3-carbonitrile (Intermediate Int A) with piperazine-1-carboxylate tert-butyl in place of (R)-2-methylpiperazine - 1-Carboxylic acid tert-butyl ester. LCMS (m/z): 426.3 (M+H).
- intermediate Int F was carried out as described in intermediate Int B1, substituting (S)-2(cyanomethyl)piperazine-1-carboxylic acid benzyl ester acid salt for (R)-2-methylpiperidine tert-butyl oxazine-1-carboxylate.
- LCMS m/z: 576.3, 578.3 (M+H).
- Step A (R)-4-(7-Bromo-6-chloro-3-cyano-8-fluoro-2-(((3R,4R)-4-methoxy-1-methylpyrrolidine- 3-yl)oxy)quinolin-4-yl)-2-methylpiperazine-1-carboxylate tert-butyl ester
- Step B (2R)-4-(7-(2-((tert-butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-3-cyano-8 -Fluoro-2-(((3R,4R)-4-methoxy-1-methylpyrrolidin-3-yl)oxy)quinolin-4-yl)-2-methylpiperazine-1- tert-butyl carboxylate
- Step C 7-(2-Amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-8-fluoro-2-((((3R,4R)-4-methoxy-1 -Methylpyrrolidin-3-yl)oxy)-4-((R)-3-methylpiperazin-1-yl)quinoline-3-carbonitrile
- Step D 4-((R)-4-Acryloyl-3-methylpiperazin-1-yl)-7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6 -Chloro-8-fluoro-2-(((3R,4R)-4-methoxy-1-methylpyrrolidin-3-yl)oxy)quinoline-3-carbonitrile
- Example 2 The synthesis of Example 2 was carried out as described in Example 1, using 4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinolin-4-yl)piperazine in step A - 1-Carboxylic acid tert-butyl ester (Intermediate B2) in place of (R)-4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinolin-4-yl)-2- Methylpiperazine-1-carboxylate tert-butyl ester (Intermediate B1).
- Step A 4-(7-Bromo-6-chloro-3-cyano-2-(3-((dimethylamino)methyl)phenyl)-8-fluoroquinolin-4-yl)piperazine- 1-Carboxylic acid tert-butyl ester
- Step B to Step D 4-(4-Acryloylpiperazin-1-yl)-7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-2-( 3-((dimethylamino)methyl)phenyl)-8-fluoroquinoline-3-carbonitrile
- Example 3 The subsequent synthesis of Example 3 was carried out as described in the synthesis of Example 1, using 4-(7-bromo-6-chloro-3-cyano-2-(3-((dimethylamino)methyl)benzene in step B) (R)-4-(7-bromo-6-chloro-3-cyano-8-fluoro-2- (((3R,4R)-4-Methoxy-1-methylpyrrolidin-3-yl)oxy)quinolin-4-yl)-2-methylpiperazine-1-carboxylate tert-butyl ester.
- Example 4 The synthesis of Example 4 was carried out as described in Example 3, using (1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)boronic acid in step A instead of (3-(( Dimethylamino)methyl)phenyl)boronic acid.
- Example 5 The synthesis of Example 5 was carried out as described in Example 3, using (3-(1-(dimethylamino)ethyl)phenyl)boronic acid in step A instead of (3-((dimethylamino)methyl) phenyl) boronic acid.
- Example 6 The synthesis of Example 6 was carried out as described in Example 3, using (R)-4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinoline-4- yl)-2-methylpiperazine-1-carboxylate tert-butyl ester (Intermediate Int B1) in place of 4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinoline- 4-yl)piperazine-1-carboxylate tert-butyl ester (Intermediate Int B2).
- Example 6 The synthesis of Example 6 was carried out as described in Example 3, using (R)-4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinoline-4- yl)-2-methylpiperazine-1-carboxylate tert-butyl ester (Intermediate Int B1) in place of 4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinoline- 4-yl)piperazine-1-carboxylate tert-butyl ester (Intermediate Int B2) and substituting (1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)boronic acid for (3 -((dimethylamino)methyl)phenyl)boronic acid.
- Step A (2R)-4-(7-(2-((tert-butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-3-cyano-8 - Fluoroquinolin-4-yl)-2-methylpiperazine-1-carboxylate tert-butyl ester
- Step B 7-(2-Amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-8-fluoro-4-((R)-3-methylpiperazin-1-yl ) quinoline-3-carbonitrile
- Step B to Step D 4-(4-Acryloylpiperazin-1-yl)-7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-8-fluoro -2-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)quinoline-3-carbonitrile
- Example 12 The synthesis of Example 12 was carried out as described in Example 8, using (5-fluoro-2-((4-methoxybenzyl)amino)quinolin-8-yl)boronic acid in step A instead of (2- ((tert-Butoxycarbonyl)amino)-7-fluorobenzothiazol-4-yl)boronic acid.
- LCMS (m/z): 519.1 (M+H).
- Example 13 The synthesis of Example 13 was carried out as described in Example 1, using 4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinolin-4-yl)piperazine in Step A - 1-Carboxylic acid tert-butyl ester (Intermediate Int B2) in place of (R)-4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinolin-4-yl)-2 - Methylpiperazine-1-carboxylate tert-butyl ester (Intermediate Int B1) and replacing the NaH mixture of (3R,4R)-4-methoxy-1-methylpyrrolidin-3-ol with sodium methoxide .
- Example 14 was carried out as described in Example 3, using (1-methyl-1H-pyrazol-5-yl)boronic acid in step A instead of (3-((dimethylamino)methyl)phenyl ) boric acid.
- 19 F NMR (376 MHz, DMSO) ⁇ -112.07, -118.03. LCMS (m/z): 591.4 (M+H).
- Example 15 The synthesis of Example 15 was carried out as described in Example 3, using (1,3-dimethyl-1H-pyrazol-4-yl)boronic acid in step A instead of (3-((dimethylamino)methyl) ) phenyl) boronic acid.
- Step A tert-Butyl 4-(7-Bromo-6-chloro-3-cyano-8-fluoro-2-methylquinolin-4-yl)piperazine-1-carboxylate
- Step B to Step D 4-(4-Acryloylpiperazin-1-yl)-7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-8-fluoro -2-Methylquinoline-3-carbonitrile
- Example 17 was carried out as described in the synthesis of Example 1, using 4-(7-bromo-6-chloro-3-cyano-8-fluoro-2-methylquinolin-4-yl) in step B Piperazine-1-carboxylate tert-butyl ester in place of (R)-4-(7-bromo-6-chloro-3-cyano-8-fluoro-2-(((3R,4R)-4-methoxy -1-Methylpyrrolidin-3-yl)oxy)quinolin-4-yl)-2-methylpiperazine-1-carboxylic acid tert-butyl ester.
- Example 18 was carried out as described in Example 3, using cyclopropylboronic acid in step A instead of (3-((dimethylamino)methyl)phenyl)boronic acid.
- Step A tert-Butyl 4-(7-Bromo-2,6-dichloro-3-cyano-8-fluoro-2-hydroxyquinolin-4-yl)piperazine-1-carboxylate
- Step B to Step D 4-(4-Acryloylpiperazin-1-yl)-7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-8-fluoro -2-Hydroxyquinoline-3-carbonitrile
- Example 19 The subsequent synthesis of Example 19 was carried out as described in the synthesis of Example 1, using 4-(7-bromo-2,6-dichloro-3-cyano-8-fluoro-2-hydroxyquinoline-4- yl)piperazine-1-carboxylate tert-butyl ester in place of (R)-4-(7-bromo-6-chloro-3-cyano-8-fluoro-2-(((3R,4R)-4-methyl Oxy-1-methylpyrrolidin-3-yl)oxy)quinolin-4-yl)-2-methylpiperazine-1-carboxylate tert-butyl ester.
- Step A 4-(7-Bromo-6-chloro-3-cyano-2-((diphenylmethylene)amino)-8-fluoroquinolin-4-yl)piperazine-1-carboxylic acid tert. Butyl ester
- Step B 4-(7-(2-((tert-butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-3-cyano-2-((di Benzylidene)amino)-8-fluoroquinolin-4-yl)piperazine-1-carboxylate tert-butyl ester
- Step C 7-(2-Amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-2-((diphenylmethylene)amino)-8-fluoro-4-( Piperazin-1-yl)quinoline-3-carbonitrile
- Step D 4-(4-Acryloylpiperazin-1-yl)-7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-2-((diphenyl Methylene)amino)-8-fluoroquinoline-3-carbonitrile
- Step E 4-(4-Acryloylpiperazin-1-yl)-2-amino-7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-8- Fluoroquinoline-3-carbonitrile
- Step A (S)-Benzyl 4-(7-Bromo-6-chloro-3-cyano-8-fluoroquinolin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (21-1) and (S)-4-(7-bromo-6-chloro-3-cyano-8-fluoro-2-hydroxyquinolin-4-yl)-2-(cyanomethyl) ) benzyl piperazine-1-carboxylate (22-1)
- Step B (2S)-4-(7-(2-((tert-butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-3-cyano-8 - Fluoroquinolin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate benzyl ester (21-2) and (2S)-4-(7-(2-((tert-butyl Oxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-3-cyano-8-fluoro-2-hydroxyquinolin-4-yl)-2-(cyano Methyl)piperazine-1-carboxylate benzyl ester (22-2)
- reaction tube was sealed, and the reaction was heated to 115 °C by microwave for 2 h. Cooled to room temperature, diluted with water (60 mL), and extracted with EA (50 mL ⁇ 3).
- Step A (4-(6-Chloro-3-cyano-4-((S)-3-(cyanomethyl)piperazin-1-yl)-8-fluoroquinolin-7-yl)- 7-Fluorobenzo[d]thiazol-2-yl)carbamate tert-butyl ester
- Step B 7-(2-Amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-4-((S)-3-(cyanomethyl)piperazin-1-yl )-8-Fluoroquinoline-3-carbonitrile
- Step C 4-((S)-4-Acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(2-amino-7-fluorobenzo[d]thiazole-4- yl)-6-chloro-8-fluoroquinoline-3-carbonitrile
- Step A 7-(2-Amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-4-((S)-3-(cyanomethyl)piperazin-1-yl )-8-Fluoro-2-hydroxyquinoline-3-carbonitrile
- Step B 4-((S)-4-Acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(2-amino-7-fluorobenzo[d]thiazole-4- yl)-6-chloro-8-fluoro-2-hydroxyquinoline-3-carbonitrile
- Example 32 The synthesis of Example 32 was carried out as described in Example 17, using (S)-4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquinoline-4- yl)-2-(cyanomethyl)piperazine-1-carboxylate benzyl ester (Intermediate F) in place of 4-(7-bromo-2,6-dichloro-3-cyano-8-fluoroquine Linn-4-yl)piperazine-1-carboxylate tert-butyl ester (Intermediate B2).
- Example 33 The synthesis of Example 33 was carried out as described in Example 20, substituting (2-((tert-butoxycarbonyl)amino)benzo[d]thiazol-4-yl)boronic acid in step B for (2-((tert-butoxycarbonyl)amino)benzo[d]thiazol-4-yl)boronic acid Butoxycarbonyl)amino)-7-fluorobenzothiazol-4-yl)boronic acid.
- Example 34 The synthesis of Example 34 was carried out as described in Example 20, using (2-((tert-butoxycarbonyl)amino)-5-fluorobenzo[d]thiazol-4-yl)boronic acid in step B instead of (2 -((tert-butoxycarbonyl)amino)-7-fluorobenzothiazol-4-yl)boronic acid.
- Step A tert-Butyl 4-(7-Bromo-6-chloro-3-cyano-8-fluoro-2-(methylamino)quinolin-4-yl)piperazine-1-carboxylate
- Step B to Step D 4-(4-Acryloylpiperazin-1-yl)-7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-8-fluoro -2-(Methylamino)quinoline-3-carbonitrile
- Example 35 The subsequent synthetic procedure of Example 35 was carried out as described in Example 19, using 4-(7-bromo-6-chloro-3-cyano-8-fluoro-2-(methylamino)quinoline in step B) -4-yl)piperazine-1-carboxylate tert-butyl ester in place of 4-(7-bromo-2,6-dichloro-3-cyano-8-fluoro-2-hydroxyquinolin-4-yl)piperidine tert-butyl oxazine-1-carboxylate.
- Example 36 The synthesis of Example 36 was as described in Example 35, using dimethylamine hydrochloride instead of methylamine hydrochloride in step A.
- 19 F NMR (376 MHz, DMSO-d 6 ) ⁇ -112.51, -120.42.
- LCMS (m/z): 554.5 (M+H).
- Step A tert-butyl 4-(2-acetamido-7-bromo-6-chloro-3-cyano-8-fluoroquinolin-4-yl)piperazine-1-carboxylate
- Step B to Step D N-(4-(4-Acryloylpiperazin-1-yl)-7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro- 3-cyano-8-fluoroquinolin-2-yl)acetamide
- Example 37 The subsequent synthetic procedure of Example 37 was carried out as described in Example 19, using 4-(2-acetamido-7-bromo-6-chloro-3-cyano-8-fluoroquinolin-4-yl in step B) ) piperazine-1-carboxylate tert-butyl ester instead of 4-(7-bromo-2,6-dichloro-3-cyano-8-fluoro-2-hydroxyquinolin-4-yl)piperazine-1- tert-butyl carboxylate.
- Step A 4-(7-Bromo-6-chloro-3-cyano-8-fluoro-2-((trimethylsilyl)ethynyl)quinolin-4-yl)piperazine-1-carboxylic acid tert-butyl ester
- Step B 4-(7-(2-((tert-butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-3-cyano-8-fluoro- 2-((Trimethylsilyl)ethynyl)quinolin-4-yl)piperazine-1-carboxylate tert-butyl ester
- Step C 4-(7-(2-((tert-butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-3-cyano-2-ethynyl -8-Fluoroquinolin-4-yl)piperazine-1-carboxylate tert-butyl ester
- Steps D and E 4-(4-Acryloylpiperazin-1-yl)-7-(2-amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-2-ethynyl -8-Fluoroquinoline-3-carbonitrile
- Step A 4-(7-(2-((tert-butoxycarbonyl)amino)-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-3-cyano-8-methoxy Quinolin-4-yl)piperazine-1-carboxylate tert-butyl ester
- Example 39 The steps of removing the protecting group and introducing the acryloyl chloride involved in the subsequent synthesis of Example 39 can basically be carried out by referring to the method described in Example 1.
- Luminescent Cell Viability Assay kit evaluates and verifies the proliferation inhibitory activity of the compounds of the present invention on KRas G12C mutated NCI-H358 human non-small cell lung cancer cells.
- a control group i.e., a culture medium control
- 3D complete medium 10% FBS in RPMI1640 solution containing 1% methylcellulose
- Control group ie, cell control
- compound AMG510 or the following reference compounds were used as positive controls. Place the cell plate in a cell incubator overnight.
- the end-point detection thaw the CellTiter-Glo reagent and move the cell plate to room temperature for 30 minutes, add 100 ⁇ L of CellTiter-Glo to each well of the cell plate, shake it on an orbital shaker for 5 minutes to fully lyse the cells, and place the cell plate on the cell plate.
- the luminescence value of each well was scanned at full wavelength with a multi-function microplate reader (Molecular Devices, Spectramax M3 microplate reader).
- Inhibition rate% [1-(Lum test drug -Lum culture medium control )/(Lum cell control -Lum culture medium control )] ⁇ 100%
- IC50 values were calculated using GraphPad Prism 7.0 software, fitting the data using nonlinear S-curve regression, resulting in a dose-response curve.
- the compounds of the present invention showed satisfactory anti-cell proliferation activity on KRas G12C-mutated NCI-H358 human non-small cell lung cancer cells.
- the tested example compounds all showed anti-cell proliferative activity with IC 50 values generally ⁇ 1 ⁇ M, such as ⁇ 0.5 ⁇ M, ⁇ 0.1 ⁇ M, preferably ⁇ 50 nM, more preferably ⁇ 20 nM, most preferably ⁇ 10 nM, for example
- Compounds of Examples 17, 20, 32, 33, 34, 37 all showed IC50 values of ⁇ 50 nM, and compounds of Examples 1, 2, 3, 5, 6, 8, 9, 10, 39 showed IC50 values of ⁇ 20 nM.
- Specific data for some representative example compounds are shown in Table 1.
- Example 1 94.7 0.015
- Example 2 97.6 0.003
- Example 3 97.7 0.009
- Example 4 94.8 0.053
- Example 5 94.9 0.007
- Example 6 95.0 0.017
- Example 7 90.0 0.26
- Example 8 94.0 0.018
- Example 9 98.8 0.0086
- Example 10 96.1 0.018 Reference Compound A 96.9 0.011 Reference Compound B / 0.35
- Example 2 Rat pharmacokinetic properties of the compounds of the present invention
- ⁇ Test material Male SD rats, age: 6-8 weeks, body weight 220-250g, purchased from Zhaoyan (Suzhou) New Drug Research Center Co., Ltd.; Tolbutamide (Aladdin, Item No. H1401054) ; Sulfobutyl ⁇ -cyclodextrin (Captisol, Shandong Binzhou Zhiyuan Bio, Cat. No. 20191013); Propylene Glycol (15) Stearate (Solutol, Meilun Bio, Cat. No. S0206A); DMSO (Vetec, Cat. No. WXBD0293V); Acetonitrile (Sigma-Aldrich, Cat. No. WXBD1744V); methanol (Sigma-Aldrich, Cat. No. WXBD2831V).
- Example analysis ⁇ Establish a compound LC-MS/MS analysis method.
- Standard curve preparation Pipet 20 ⁇ L of 1mg/mL DMSO stock solution for each compound, transfer it to 900 ⁇ L of 50% methanol working solution, and dilute step by step to obtain a concentration of 20000, 10000, 5000, 1000, 500, 100, 50, 20 , 10ng/mL standard curve working solution, then draw 5 ⁇ L standard curve working solution and mix with 45 ⁇ L rat blank plasma to obtain a standard concentration of 2000, 1000, 500, 100, 50, 10, 5, 2, 1ng/mL Curve, used to quantify unknown samples.
- Sample pretreatment 50 ⁇ L unknown plasma sample and standard curve sample, add 250 ⁇ L acetonitrile containing internal standard as a precipitant, precipitate plasma protein, extract the test compound in the plasma, centrifuge at low temperature for 20 minutes, take the supernatant, mix the supernatant with 0.1% formic acid aqueous solution was mixed, and 5 ⁇ L was injected to analyze the blood concentration of the drug.
- Compound AMG510 Prepared as described in Lanman B et al, J. Med. Chem. 2020, 63, 52-65.
- Example 9 has excellent pharmacokinetic properties, as shown in Table 3 for details.
- Example 3 Antitumor activity of compounds of the present invention in human non-small cell lung cancer NCI-H358 xenograft mouse model
- This experiment evaluated and verified the proliferation inhibitory activity of the compounds of the present invention in the human non-small cell lung cancer NCI-H358 xenograft mouse model.
- the NCI-H358 cell line carries the KRAS G12C mutation, which was provided by Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd. (from ATCC, product number CRL-5807).
- mice 6-8 week old female NPSG mice were subcutaneously inoculated on the right shoulder with 5 ⁇ 10 6 NCI-H358 cells (containing 50% Matrigel) in an inoculation volume of 0.1 mL.
- NCI-H358 cells containing 50% Matrigel
- Dosing was started immediately after grouping, and the day of dosing was regarded as day 0.
- Dosing was given once a day by gavage at a dose of 10 mg/kg or a solvent control (10% cyclodextrin in 50 mM citrate buffer pH 5.0). During the experiment, tumor volume and body weight were measured twice a week.
- Average tumor inhibition rate TGI% [(C mean -C 0 mean )-(T mean -T 0 mean )]/(C mean -C 0 mean )*100%, where T is the administration group tumor volume, T 0 is the initial tumor volume of the administration group, C is the tumor volume of the control group, and C 0 is the initial tumor volume of the control group.
- Embodiment 4 the compound of the present invention to cytochrome P450 inhibition test
- ⁇ Test materials Human liver microsomes (Corning company, product number 452161); reduced nicotinamide adenine dinucleotide phosphate (NADPH, MCE company, product number HY-F0003/CS-4998); phenacetin, double Chlorophenolic acid, ⁇ -naphthoflavone, omeprazole and ketoconazole were purchased from TCI; S-mephenytoin and testosterone were purchased from CAYMAN; midazolam was purchased from Bioreclamation IVT; quinidine was purchased from Damas -beta; sulfaphenazole was purchased from MCE; bufurolol was purchased from TRC.
- K-buffer 100 mM potassium phosphate buffer (K-buffer) was prepared with potassium dihydrogen phosphate and dipotassium hydrogen phosphate, and the pH was adjusted to 7.4.
- To make up 400X test compound and reference inhibitor Dissolve 8 ⁇ L of a 10 mM stock of test compound in 12 ⁇ L of acetonitrile.
- 4 ⁇ NADPH potassium phosphate solution 66.7mg NADPH was added to 10mL 0.1M K-buffer, pH 7.4.
- Preparation of 4x substrate potassium phosphate solution prepare different substrates according to the concentration requirements with 10mL of 0.1M K-buffer to prepare the solution required for 4x concentration determination.
- HMM human liver microsomes
- Example 5 The proliferation inhibitory effect of the compounds of the present invention on a series of KRas mutant cells
- the CellTiter-Glo (CTG) kit of Promega Company was used to evaluate the antiproliferative activity of the representative compounds of the present invention on 12 KRas mutant tumor cell lines.
- ⁇ Test materials RPMI1640 medium (Hyclone, product number SH30809.01); fetal bovine serum (FBS) (Gibco, product number 10099-141); phosphate buffered saline PBS (Solarbio, product number P1020-500); DMSO (Sigma, Cat. No. D8418-1L); Assay Kit CTG (Promega, Cat. No. G7573); 96-well cell culture plate (Thermo, Cat. No. 165305); Shaker (QILINBEIER, Cat. No. QB-9001); Cell incubator (Thermo Scientific, Cat. No. Model 3100 Series); microscope (OLYMPUS, cat. no.
- CKX41SF multi-plate reader
- BMG LABTECH cat. no. Plus
- biological safety cabinet Thermo, Cat. No. Model 1300 Series A2.
- Various cell lines used in the following experiments were purchased from Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd.
- Each of the above cell lines was cultured in the indicated complete medium at 37°C, 5% CO 2 , and cells in logarithmic growth phase were harvested and counted using a platelet counter. Cell viability was detected by trypan blue exclusion method to ensure cell viability was above 90%. Cell density was adjusted using complete medium and then seeded in 96-well cell culture plates at 90 ⁇ L per well for a total of 3000 cells. Cells in 96-well plates were cultured at 37°C, 5% CO2 .
- Inhibition rate% [1-(Lum test drug -Lum culture medium control )/(Lum cell control -Lum culture medium control )] ⁇ 100%
- Example 6 Inhibitory effect of the compounds of the present invention on the proliferation of KRas G12C inhibitor-resistant model cells
- the CellTiter-Glo (CTG) kit provided by Promega was used to evaluate the effect of the test compounds on the cell proliferation of 5 KRas cell lines (with acquired resistance to the KRas G12C inhibitor Adagrasib), and the reference compounds A and AMG510 served as control compounds.
- Example 5 The experimental materials and instruments used are the same as those listed in Example 5 above.
- the various cell lines used in this experiment were from Kangyuan Bochuang Biotechnology (Beijing) Co., Ltd.
- Example 7 Using the same method and conditions as Example 5, the cell growth inhibitory activity of the test compound was investigated, and the results are shown in Table 7.
- Example 7 In vivo pharmacodynamic study of the compounds of the present invention on human pancreatic cancer Mia PaCa-2 cells subcutaneously xenografted tumor BALB/c nude mice model
- ⁇ Test material BALB/c nude mice, 6-8 weeks old, female, Zhejiang Weitong Lihua Laboratory Animal Technology Co., Ltd. Human pancreatic cancer Mia PaCa-2 cells (ATCC, Cat. No. CRL-1420). Matrigel (Matrigel, Corning, Cat. No. 356234).
- TGI (%) [1-(the average tumor volume at the end of the treatment group-the average tumor volume at the beginning of the treatment group)/(solvent control) The average tumor volume at the end of treatment in the control group - the average tumor volume in the solvent control group at the beginning of treatment)] ⁇ 100%.
- Example 9 Group Tumor volume (mm 3 ) (day 21) TGI(%) solvent control 1202 / Example 9 (30mpk) 162 97.7% Example 9 (10mpk) 246 89.8% Example 9 (3mpk) 665 50.4% AMG510 (10mpk) 432 72.3% .
Abstract
Description
化合物 | 抑制率%(1μM) | IC 50(μM) |
实施例1 | 94.7 | 0.015 |
实施例2 | 97.6 | 0.003 |
实施例3 | 97.7 | 0.009 |
实施例4 | 94.8 | 0.053 |
实施例5 | 94.9 | 0.007 |
实施例6 | 95.0 | 0.017 |
实施例7 | 90.0 | 0.26 |
实施例8 | 94.0 | 0.018 |
实施例9 | 98.8 | 0.0086 |
实施例10 | 96.1 | 0.018 |
参比化合物A | 96.9 | 0.011 |
参比化合物B | / | 0.35 |
实施例 | T 1/2(h) | AUC 0-t(ng·hr/mL) | Cl(mL/min/kg) |
1 | 2.87 | 657 | 20.9 |
9 | 0.67 | 1047 | 15.8 |
10 | 2.66 | 592 | 27.4 |
13 | 1.37 | 1946 | 8.58 |
14 | 1.58 | 1096 | 15.1 |
15 | 1.03 | 717 | 23.3 |
16 | 3.5 | 2787 | 5.93 |
参比化合物A | 1.00 | 623 | 27.1 |
AMG510 | 0.49 | 231 | 71.8 |
组别 | 肿瘤体积(mm 3)(第14天) | TGI(%) |
溶剂对照组 | 1170 | / |
实施例1 | 478.4 | 71 |
实施例2 | 497.3 | 69 |
实施例8 | 519.2 | 67 |
AMG510 | 525.1 | 66 |
细胞系 | 突变类型 | 组织来源 | 生长特点 | 完全培养基 |
H23 | KRas-G12C | 肺 | 贴壁 | RPMI-1640+10%FBS |
H1373 | KRas-G12C | 肺 | 贴壁 | RPMI-1640+10%FBS |
MIA-Paca-2 | KRas-G12C | 胰腺 | 贴壁 | DMEM+10%FBS |
SW837 | KRas-G12C | 结直肠 | 贴壁 | RPMI-1640+10%FBS |
Kyse-410 | KRas-G12C | 食管 | 贴壁 | RPMI-1640+10%FBS |
HCT116 | KRas-G13D | 结直肠 | 贴壁 | RPMI-1640+10%FBS |
T84 | KRas-G13D | 结直肠 | 贴壁 | DMEM+10%FBS |
A549 | KRasG12S | 肺 | 贴壁 | DMEM+10%FBS |
细胞系 | 细胞系类型 | 生长特点 | 完全培养基 |
BaF3-KRas-G12C-Y96C | 小鼠原B细胞 | 悬浮 | RPMI-1640+10%FBS |
BaF3-KRas-G12C-Y96D | 小鼠原B细胞 | 悬浮 | RPMI-1640+10%FBS |
BaF3-KRas-G12C-R68S | 小鼠原B细胞 | 悬浮 | RPMI-1640+10%FBS |
BaF3-KRas-G12C-H95Q | 小鼠原B细胞 | 悬浮 | RPMI-1640+10%FBS |
BaF3-KRas-G12C-H95D | 小鼠原B细胞 | 悬浮 | RPMI-1640+10%FBS |
组别 | 肿瘤体积(mm 3)(第21天) | TGI(%) |
溶剂对照组 | 1202 | / |
实施例9(30mpk) | 162 | 97.7% |
实施例9(10mpk) | 246 | 89.8% |
实施例9(3mpk) | 665 | 50.4% |
AMG510(10mpk) | 432 | 72.3% |
Claims (24)
- 式(I)的化合物,其中,A选自C-R a或N,其中R a选自卤素、CN、硝基、C 3-6环烷基或任选被卤素取代的C 1-6烷基;R 1、R 2和R 3各自独立地选自H、卤素或C 1-6烷基,其中所述烷基任选被独立地选自卤素、-N(R c) 2、-OR c或3-8元杂环烷基的基团取代;R b在每次出现时独立地选自H、卤素、CN或任选被卤素或CN取代的C 1-6烷基;X选自键、-O-或-NH-;R 4选自H、卤素、C 1-6烷基、-C 0-6烷基-C 6-10芳基、-C 0-6烷基-C 3-8环烷基、-C 0-6烷基-C 3-8环烯基、-C 0-6烷基-3-8元杂环烷基、-C 0-6烷基-3-8元杂环烯基、-C 0-6烷基-5-10元杂芳基,其中所述烷基、芳基、环烷基、环烯基、杂环烷基、杂环烯基和杂芳基任选被独立地选自以下的一个或多个基团取代:卤素、任选被卤素取代的C 1-6烷基、-(CR cR c) 0-6-SR c、-(CR cR c) 0-6-(CO) 0- 1-OR c、-(CR cR c) 0-6-(CO) 0-1-N(R c) 2,其中连接于芳基、环烷基、环烯基、杂环烷基、杂环烯基或杂芳基上的-(CR cR c) 0-6-(CO) 0-1-N(R c) 2任选通过其中N上连接的基团、连同与其所连接的环状基团上的原子及相邻的原子一起形成4-7元含氮杂环;R c在每次出现时独立地选自H或任选被卤素取代的C 1-6烷基,或者其中连接在同一个碳原子或氮原子上的两个R c各自独立地与它们所连接的碳原子或氮原子一起形成3-6元环状基团;E选自卤素、-O-R d或-N(R d) 2-,其中R d各自独立地为H或任选被卤素取代的C 1-6烷基;m为0或1;B和D各自独立地选自N或C;Z、G和Y各自独立地选自C、N、O或S;R 6、R 7和R 8各自独立地选自H、卤素和任选被卤素取代的C 1-6烷基;条件是,B和D不同时为N;且Z、G、Y、D、B中至多三个不为C;或其异构体、药学上可接受的盐或溶剂合物。
- 根据权利要求1的式(I)化合物或其异构体、药学上可接受的盐或溶剂合物,其中A为N或C-R a,其中R a选自卤素,优选Cl。
- 根据权利要求1或2的式(I)化合物或其异构体、药学上可接受的盐或溶剂合物,其中R 1选自H或卤素,优选H或F。
- 根据权利要求1-3任一项的式(I)化合物或其异构体、药学上可接受的盐或溶剂合物,其中R b为H;或存在一个R b且R b为CN或任选被CN取代的C 1-6烷基;或存在两个R b且R b为C 1-6烷基。
- 根据权利要求1-4任一项的式(I)化合物或其异构体、药学上可接受的盐或溶剂合物,其中R 4选自H、卤素、C 1-6烷基、苯基、C 3-6环烷基、包含1、2或3个独立地选自N、O或S的杂原子的4-6元杂环烷基和包含1、2或3个独立地选自N、O或S的杂原子的5-6元杂芳基,其中所述烷基、苯基、环烷基、杂环烷基和杂芳基任选被独立地选自以下的1、2或3个基团取代:卤素、任选被卤素取代的C 1-6烷基、-(CR cR c) 0-6-OR c和-(CR cR c) 0-6-N(R c) 2,其中R c在每次出现时独立地选自H或C 1-6烷基。
- 根据权利要求1-5任一项的式(I)化合物或其异构体、药学上可接受的盐或溶剂合物,其中E为卤素,优选为F,或E为-O-R d,R d为任选被卤素取代的C 1-6烷基。
- 根据权利要求7的式(I)化合物或其异构体、药学上可接受的盐或溶剂合物,其中R 6、R 7和R 8中至少一个是卤素,优选F。
- 式(II)化合物或其异构体、药学上可接受的盐或溶剂合物,其中:A选自C-R a或N,其中R a选自卤素;R 1、R 2和R 3各自独立地选自H、卤素或C 1-6烷基;R b在每次出现时独立地选自H、卤素、CN或任选被卤素或CN取代的C 1-6烷基;X选自键、-O-或-NH-;R 4选自H、卤素、C 1-6烷基、-C 0-3烷基-C 6-10芳基、-C 0-3烷基-C 3-8环烷基、-C 0-3烷基-C 3-8环烯基、-C 0-3烷基-包含1、2或3个独立的选自N、O或S的杂原子的3-8元杂环烷基、-C 0- 3烷基-包含1、2或3个独立的选自N、O或S的杂原子的3-8元杂环烯基、-C 0-3烷基-包含1、2或3个独立的选自N、O或S的杂原子的5-10元杂芳基,其中所述烷基、芳基、环烷基、环烯基、杂环烷基、杂环烯基和杂芳基任选被独立地选自以下的1、2或3个基团取代:卤素、任选被卤素取代的C 1-6烷基、-(CR cR c) 0-6-OR c、-(CR cR c) 0-6-N(R c) 2,其中连接于芳基、环烷基、环烯基、杂环烷基、杂环烯基或杂芳基上的-(CR cR c) 0-6-N(R c) 2任选通过其中N上连接的基团、连同与其所连接的环状基团上的原子及相邻的原子一起形成4-7元含氮杂环;R c在每次出现时独立地选自H或任选被卤素取代的C 1-6烷基;E选自卤素、-O-R d或-N(R d) 2-,其中R d各自独立地为H或任选被卤素取代的C 1-6烷基;R 6、R 7和R 8各自独立地选自H、卤素和任选被卤素取代的C 1-6烷基;或其异构体、药学上可接受的盐或溶剂合物。
- 根据权利要求10的式(II)化合物或其异构体、药学上可接受的盐或溶剂合物,其中A为C-R a,其中R a为卤素,优选Cl。
- 根据权利要求10的式(II)化合物或其异构体、药学上可接受的盐或溶剂合物,其中R 6、R 7和R 8中至少一个是卤素,优选F。
- 根据权利要求12的式(II)化合物或其异构体、药学上可接受的盐或溶剂合物,其中R 6为F,且R 7和R 8为H。
- 根据权利要求10的式(II)化合物或其异构体、药学上可接受的盐或溶剂合物,其中E是卤素,优选F。
- 根据权利要求10的式(II)化合物或其异构体、药学上可接受的盐或溶剂合物,其中E是-O-R d,R d为任选被卤素取代的C 1-6烷基。
- 根据权利要求10-15任一项的式(II)化合物或其异构体、药学上可接受的盐或溶剂合物,其中R 4选自H、卤素、C 1-6烷基、苯基、C 3-6环烷基、包含1、2或3个独立的选自N、O或S的杂原子的4-6元杂环烷基和包含1、2或3个独立的选自N、O或S的杂原子的5-6元杂芳基,其中所述烷基、芳基、环烷基、杂环烷基和杂芳基任选被独立地选自以下的1、2或3个基团取代:卤素、任选被卤素取代的C 1-6烷基、-(CR cR c) 0-6-OR c和-(CR cR c) 0-6-N(R c) 2,其中连接于芳基、环烷基、环烯基、杂环烷基、杂环烯基或杂芳基上的-(CR cR c) 0-6-N(R c) 2任选通过其中N上连接的基团、连同与其所连接的环状基团上的原子及相邻的原子一起形成4-7元含氮杂环。
- 药物组合物,包含根据权利要求1-17任一项的化合物、其异构体或它们药学上可接受的盐或溶剂合物,以及药学上可接受的赋形剂。
- 根据权利要求1-17任一项的化合物、其异构体或它们药学上可接受的盐或溶剂合物,用作药物,优选用于治疗和/或预防由KRas突变、优选KRas G12C突变介导的疾病。
- 治疗和/或预防由Ras突变、优选KRas G12C介导的疾病的方法,包括向有需要的对象施用治疗有效量的根据权利要求1-17任一项的化合物、其异构体或它们药学上可接受的盐或溶剂合物或根据权利要求18的药物组合物。
- 根据权利要求1-17任一项的化合物、其异构体或它们药学上可接受的盐或溶剂合物或根据权利要求18的药物组合物用于预防或治疗由KRas突变、优选KRas G12C突变介导的疾病的用途。
- 根据权利要求1-17任一项的化合物、其异构体或它们药学上可接受的盐或溶剂合物或根据权利要求18的药物组合物在制备用于预防或治疗由KRas突变、优选KRas G12C突变介导的疾病的用药物中的用途。
- 根据权利要求21或22的用途,其中由KRas突变、优选KRas G12C突变介导的疾病选自肺癌、肺腺癌、骨癌、胰腺癌、皮肤癌、头颈癌、皮肤或眼内黑素瘤、子宫癌、卵巢癌、直肠癌、肛门区域癌、胃癌、结肠癌、乳腺癌、输卵管癌、子宫内膜癌、子宫颈癌、阴道癌、外阴癌、霍奇金病、食道癌、小肠癌、内分泌系统癌、甲状腺癌、甲状旁腺癌、肾上腺癌、软组织肉瘤、尿道癌、阴茎癌、前列腺癌、慢性或急性白血病、淋巴细胞性淋巴瘤、膀胱癌、肾脏或输尿管癌、肾细胞癌、肾盂癌、中枢神经系统肿瘤(CNS)、原发性CNS淋巴瘤、脊柱肿瘤、脑干神经胶质瘤或垂体腺瘤。
- 根据权利要求23的用途,其中由KRas突变、优选KRas G12C突变介导的疾病选自肺腺癌、肺癌、结肠癌、直肠癌、胰腺癌、胆管癌、子宫内膜癌、卵巢癌、白血病;最优选选自肺腺癌、结肠癌、直肠癌、胰腺癌、胆管癌。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/035,341 US20230406849A1 (en) | 2020-11-06 | 2021-11-05 | Kras inhibitors for treatment of cancers |
EP21888652.1A EP4242207A1 (en) | 2020-11-06 | 2021-11-05 | Kras inhibitors for treatment of cancers |
JP2023526934A JP2023547522A (ja) | 2020-11-06 | 2021-11-05 | がんの治療のためのKRas阻害剤 |
CN202180074854.2A CN116867779A (zh) | 2020-11-06 | 2021-11-05 | 用于癌症治疗的KRas抑制剂 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011229677 | 2020-11-06 | ||
CN202011229677.4 | 2020-11-06 | ||
CN202111280310.XA CN114920738A (zh) | 2020-11-06 | 2021-11-01 | 用于癌症治疗的KRas抑制剂 |
CN202111280310.X | 2021-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022095960A1 true WO2022095960A1 (zh) | 2022-05-12 |
Family
ID=81457512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/128977 WO2022095960A1 (zh) | 2020-11-06 | 2021-11-05 | 用于癌症治疗的KRas抑制剂 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230406849A1 (zh) |
EP (1) | EP4242207A1 (zh) |
JP (1) | JP2023547522A (zh) |
CN (1) | CN116867779A (zh) |
TW (1) | TW202233188A (zh) |
WO (1) | WO2022095960A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022232332A1 (en) * | 2021-04-29 | 2022-11-03 | Amgen Inc. | 2-aminobenzothiazole compounds and methods of use thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106488910A (zh) * | 2013-10-10 | 2017-03-08 | 亚瑞克西斯制药公司 | Kras g12c的抑制剂 |
CN107849022A (zh) * | 2015-04-10 | 2018-03-27 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物和其使用方法 |
CN108779097A (zh) * | 2015-11-16 | 2018-11-09 | 亚瑞克西斯制药公司 | 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法 |
US20190144444A1 (en) | 2017-11-15 | 2019-05-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
WO2019110751A1 (en) | 2017-12-08 | 2019-06-13 | Astrazeneca Ab | Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents |
CN110869357A (zh) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
CN110869358A (zh) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
WO2020081282A1 (en) | 2018-10-15 | 2020-04-23 | Eli Lilly And Company | Kras g12c inhibitors |
CN112142735A (zh) * | 2020-04-09 | 2020-12-29 | 上海凌达生物医药有限公司 | 一类稠和氰基吡啶类化合物、制备方法和用途 |
CN113563323A (zh) * | 2020-04-29 | 2021-10-29 | 上海凌达生物医药有限公司 | 一类苯并噻唑基联芳基类化合物、制备方法和用途 |
-
2021
- 2021-11-05 US US18/035,341 patent/US20230406849A1/en active Pending
- 2021-11-05 JP JP2023526934A patent/JP2023547522A/ja active Pending
- 2021-11-05 WO PCT/CN2021/128977 patent/WO2022095960A1/zh active Application Filing
- 2021-11-05 CN CN202180074854.2A patent/CN116867779A/zh active Pending
- 2021-11-05 EP EP21888652.1A patent/EP4242207A1/en active Pending
- 2021-11-05 TW TW110141361A patent/TW202233188A/zh unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106488910A (zh) * | 2013-10-10 | 2017-03-08 | 亚瑞克西斯制药公司 | Kras g12c的抑制剂 |
CN107849022A (zh) * | 2015-04-10 | 2018-03-27 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物和其使用方法 |
CN108779097A (zh) * | 2015-11-16 | 2018-11-09 | 亚瑞克西斯制药公司 | 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法 |
CN110869357A (zh) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
CN110869358A (zh) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
US20190144444A1 (en) | 2017-11-15 | 2019-05-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
WO2019110751A1 (en) | 2017-12-08 | 2019-06-13 | Astrazeneca Ab | Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents |
WO2020081282A1 (en) | 2018-10-15 | 2020-04-23 | Eli Lilly And Company | Kras g12c inhibitors |
CN112142735A (zh) * | 2020-04-09 | 2020-12-29 | 上海凌达生物医药有限公司 | 一类稠和氰基吡啶类化合物、制备方法和用途 |
CN113563323A (zh) * | 2020-04-29 | 2021-10-29 | 上海凌达生物医药有限公司 | 一类苯并噻唑基联芳基类化合物、制备方法和用途 |
Non-Patent Citations (15)
Title |
---|
"McGraw-Hill Dictionary of Chemical Terms", 1984, MCGRAW-HILL BOOK COMPANY |
ALAMGEER ET AL., CURRENT OPIN PHARMACOL, vol. 13, 2013, pages 394 - 401 |
ANSEL, HOWARD C. ET AL.: "Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems", 2004, WILLIAMS& WILKINS |
BUNDGARD, H.: "Design of Prodrugs", 1985, ELSEVIER, pages: 7 - 9,21-24 |
CHANG, E.H. ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 79, no. 16, 1982, pages 4848 - 4852 |
DUAN NI ET AL., PHARMACOLOGY & THERAPEUTICS, Retrieved from the Internet <URL:https://doi.org/10.1016/j.pharmthera.2019.06.007> |
E.L. ELIELS. H. WILENL.N. MANDER'S: "Stereochemistry of Organic Compounds", 1994, WILEY-INTERSCIENCE |
EDWARD B. ROCHE: "Bioreversible Carriers in Drug Design", 1987, PHARMACEUTICAL ASSOCIATION |
ENGL J MED, vol. 384, 2021, pages 2382 - 93 |
HIGUCHI, T. ET AL., ACS SYMPOSIUM, vol. 14 |
JOHN P. O'BRYAN ET AL., PHARMACOLOGICAL RESEARCH, vol. 139, 2019, pages 503 - 511 |
LANMAN B., J. MED. CHEM., vol. 63, 2020, pages 52 - 65 |
MCCORMICK, F. ET AL., CLINICAL CANCER RESEARCH, vol. 21, no. 8, 2015, pages 1797 - 1801 |
T. W. GREENEP. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS |
ZHI TAN ET AL., MINI-REVIEWS IN MEDICINAL CHEMISTRY, vol. 16, 2016, pages 345 - 357 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022232332A1 (en) * | 2021-04-29 | 2022-11-03 | Amgen Inc. | 2-aminobenzothiazole compounds and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
US20230406849A1 (en) | 2023-12-21 |
TW202233188A (zh) | 2022-09-01 |
EP4242207A1 (en) | 2023-09-13 |
CN116867779A (zh) | 2023-10-10 |
JP2023547522A (ja) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7311228B2 (ja) | Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 | |
CN113637005A (zh) | 用于癌症治疗的kras抑制剂 | |
CN114269735B (zh) | 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用 | |
TWI409268B (zh) | 醫藥化合物 | |
US9890168B2 (en) | 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
IL293962A (en) | Mutant kras protein inhibitors | |
TWI697490B (zh) | 用於作為shp2抑制劑之新穎雜環衍生物 | |
JP2008507534A (ja) | フラノピリジン誘導体および使用方法 | |
WO2017148440A1 (zh) | 作为flt3抑制剂的蝶啶酮衍生物及应用 | |
JP2007502820A (ja) | N−置換ピラゾリル−アミジル−ベンズイミダゾリルc−Kit阻害剤 | |
CN110650959B (zh) | 治疗化合物和组合物及其使用方法 | |
CN113195471B (zh) | 多取代吡啶酮类衍生物及其在医药上的应用 | |
WO2014090692A1 (en) | Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer | |
CN110678467A (zh) | 治疗化合物和组合物及其使用方法 | |
JP2007502822A (ja) | c−Kit阻害剤としてのN3−置換イミダゾピリジン誘導体 | |
JP7434249B2 (ja) | 複素環化合物 | |
TW201917129A (zh) | 含吡唑基的三并環類衍生物、其製備方法和應用 | |
WO2020125759A1 (zh) | 作为wnt信号通路抑制剂的化合物及其医学应用 | |
WO2022095960A1 (zh) | 用于癌症治疗的KRas抑制剂 | |
US20220017520A1 (en) | Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine | |
CN112585138A (zh) | 可用于治疗癌症的作为ErbB调节剂的4-取代的吡咯并[2,3-b]吡啶 | |
WO2022089406A1 (zh) | 含氮稠杂环类化合物及其制备方法和应用 | |
CN111587250A (zh) | 作为jak抑制剂的吡唑并嘧啶化合物 | |
WO2022037694A1 (zh) | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 | |
CN114920738A (zh) | 用于癌症治疗的KRas抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21888652 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023526934 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180074854.2 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021888652 Country of ref document: EP Effective date: 20230606 |